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Abstract 
 
The unbiased generation of specific and meaningful hypotheses from the deluge 
of data generated by modern genomic methods remains a challenge. These datasets 
require increasing level of expertise to analyze fully, and are often underutilized even 
in the originating lab. It would be desirable to have a computational strategy that is 
easy to implement, robust against outliers and missing data, and broadly applicable to 
diverse experimental designs. In this dissertation, I present a set of ranksum 
statistics-based analytical methods as a framework to extract testable hypotheses from 
large and complex datasets. To illustrate its utility, this framework was applied to two 
clinically important biological questions. In both instances, my method yielded novel 
molecular mechanisms that were subsequently validated with both in vitro and in vivo 
experiments. In the first study, gene expression profiles from multiple mouse models 
of cardiac hypertrophy were analyzed to reveal a novel interaction between 
transcription factors Nkx2-5 and Egr1, providing mechanistic insight into how Nkx2-5 
haploinsufficiency leads to exacerbated cardiac hypertrophy and poor survival in 
these mice. In the second study, thousands of microarray samples acquired from 
public data repositories were analyzed to quantitatively define tissue-specific 
expression pattern for every gene represented on a microarray platform. The 
tissue-specific expression data was then used to identify novel transcriptional 
regulators of brown fat gene expression program in adipocytes. The successful 
application of the analytical framework in these examples, regardless of their differing 
experimental design, highlights its adaptability in facilitating discoveries in a wide 
array of biological problems. 
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Chapter 1. Introduction 
Obesity 
Obesity is an epidemic 
Obesity is a condition where excessive body fat accumulation negatively impacts 
a person’s health. The most commonly used measure of obesity is based on the body 
mass index (BMI), which is a ratio between a subject’s weight in kilograms and the 
square of the subject’s height in meters, although an excess of body mass may not be 
attributed to an excess of body fat in every case. The center for Disease Control and 
Prevention defines a BMI between 25 and 30 as overweight, and a BMI greater than 
30 as obese. The 2007-2008 National Health and Nutrition Examination Survey, 
which sampled from the entire U.S. population 1, placed the prevalence of obesity at 
33.8% and the combined prevalence of overweight and obesity at 68%. Since the 
inception of the survey in the 1960’s, the prevalence of obesity has been on a steady 
linear incline, and has since then doubled. In the same period, the prevalence of 
obesity in children and adolescents has tripled to 16.9% in 2008. This is an alarming 
trend since obese children tend to become obese adults. Obesity is a risk factor in a 
plethora of diseases including coronary heart disease, hypertension, stroke, and type 2 
diabetes, and is a major contributor to mortality. In the overweight and the obese, it is 
estimated that each 5kg/m2 increase BMI translates to a 30% increase in all-cause 
mortality 2. On average, a BMI increase from 24 to 32 leads to a loss of three years in 
life expectancy. The health care cost attributed to obesity is estimated to be $147 
billion per year in 2008 3. 
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Causes and Treatments of Obesity 
In animals, unspent energy intake is stored as triacylglycerols (TAGs) in the 
adipose tissue as an evolutionary solution to the scarcity of food in the environment. 
Obesity, therefore, is a consequence of both the unbalanced caloric homeostasis, and 
the individual’s response to the unbalance as dictated by genetic and environmental 
variables. Rare monogenic causes of obesity exist, such as defects in genes involved 
in the leptin signaling pathway which regulates appetite. In the majority of cases, 
obesity is a complex condition associated with multiple contributing factors. The 
prevalence of obesity differs in subpopulations defined by ethnicity, gender, age, and 
socio-economic status 1,4. Studies following twins reared apart reported only slightly 
lowered correlation in BMI between the siblings compared to twins reared together, 
suggesting strong genetic influences 5,6. A contrasting study, however, showed that 
obesity can spread among non-related members in social networks, potentially 
through shared environment and behavior 7. Recent papers showed the composition of 
gut flora is altered in obese mice compared to the lean mice 8,9. While gut flora 
composition and the BMI of the host have an interdependent and complex relationship, 
these observations nevertheless open the possibility that obesity may be transmitted 
between individuals in this fashion. Currently, options to treat obesity are limited. 
Drugs which suppress appetite or fat absorption have questionable efficacy. Surgical 
interventions are dangerous and available only to the most severe cases. Lifestyle 
modification, which is the most effective and safe measure for the prevention and 
treatment of obesity, is difficult to implement. Novel therapeutic strategies that 
overcome the drawbacks in existing therapies are therefore desired. 
White adipose tissue is a regulatory organ of metabolism 
In obese individuals, the increase in adiposity occurs mainly in white adipose 
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tissues (WAT). In the body, WAT is distributed in discrete depots that are different 
from each other in composition and properties 10,11. WAT consists mainly of white 
adipocytes and little connective tissues. White adipocytes each feature a single large 
lipid droplet where excess calories are stored as TAGs. In addition to being the energy 
reservoir in the body, WAT is increasingly recognized as an endocrine organ. The 
adipocytes produce a number of cytokines and chemokines, as well as other secreted 
factors known as adipokines 12. Adipokines such as leptin and adiponectin are 
regulators of energy intake and metabolism. Leptin, encoded by the ob gene, relays 
satiety signal from WAT to the brain to suppress appetite 13. Adipokines have also 
been implicated in disease processes. Adiponectin, for example, is protective against 
type 2 diabetes 14. In obesity, adiposity increases to cause hypertrophy in the 
adipocytes which precedes eventual adipocyte hyperplasia. The pathology of obesity, 
however, is not merely the quantitative increase in WAT fat content. Another 
hallmark of obesity is the dysregulation of secretory factors. The serum level of 
adiponectin, for example, is inversely proportional to body fat percentage 14. Obese 
WAT additionally up-regulates chemokines such CCL2 15. Increased secretion of 
CCL2 leads to macrophage infiltration in WAT, resulting in the inflammation process 
which is another qualitative changes occurring in obese WAT. 
Brown fat as treatment for obesity 
Brown adipose tissue (BAT) shares the ability to uptake lipids with WAT but is 
structurally and functionally distinct. BAT acquires its appearance from the 
abundance of mitochondria in brown adipocytes. Uncoupling protein 1 (Ucp1), a 
BAT-specific protein, is uniquely expressed in these mitochondria to uncouple the 
electron transport from ATP production to generate heat. In this regard, brown 
adipocytes resemble cardiomyocytes in that both are metabolically active organ with 
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high mitochondrial content. The former converts chemical energy from fat into 
thermo energy while the latter into mechanical work. Small mammals rely on BAT to 
maintain thermo homeostasis as they are incapable of shivering. Human infants also 
possess appreciable amount of BAT estimated at 5% of body weight, most of which is 
lost by adulthood. Several recent discoveries have casted the BAT as a potential 
therapy for obesity. First, PET scan on workers frequently exposed cold environment 
showed increased BAT mass; suggesting the endogenous BAT may be activated in 
adults. Second, dispersed brown fat clusters are found in the WAT depots in mice 
subjected to cold-exposure or β-stimulation. Whether these ‘brite’ adipocytes 
originate from of white adipocytes or circulating stem cells is undetermined, they are 
distinct from brown adipocytes found in BAT depots. Third, recent works have 
delineated much of the gene regulatory networks required to specify brown adipocyte 
cell fate from the common progenitor cells shared with skeletal myocytes. In 
particular, the transcription regulator Prdm16 is sufficient to drive the brown fat gene 
program in a variety of cells. It is estimated that activation of half of the endogenous 
BAT complement in a typical adult can expend energy equivalent to 4 kilogram of 
body fat per year. Chemical or genetic interventions designed to activate endogenous 
BAT or BAT-like clusters in WAT would thus be a powerful tool to combat the 
obesity epidemic.  
Heart Failure 
Heart failure and intervention 
Heart failure is a serious condition where the heart is unable to pump sufficient 
amount of blood through the systemic circulation to meet the needs of the body. Heart 
failure represents a major public health challenge both domestically and abroad. 
Longitudinal data collected since the 1960’s have shown a steady increase in the 
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prevalence of heart failure, which is currently estimated to affect 5.7 million in the 
U.S 16 and 22 million worldwide, despite continuing improvement in heart failure 
therapeutics. Ironically, the increases in the prevalence of heart failure have been 
attributed to advances in treatments for other cardiovascular diseases since these 
patients can now survive with their conditions long enough to develop heart failure. 
Current standard of care for treating heart failure patients includes use of ACE 
inhibitor and β-blockers for those in the early stages of the disease. In the most severe 
cases, surgical interventions such as implantation of left ventricular assist devices or 
cardiac transplantations are needed. Despite their remarkable efficacy in prolonging 
patients’ lives, modern heart failure treatments merely slow the progression of the 
disease but cannot halt or reverse the pathogenic processes. As a result, prognosis for 
heart failure patients remains poor. In the four decades following the first availability 
of the aforementioned treatments in the 1960’s, the survival rate at five years after the 
initial diagnosis only improved from 70% to 59% 17, which is still worse than most 
forms of cancer 18. Although a large body of knowledge describing the molecular 
basis of heart failure has accumulated, it is likely that other important pathogenic 
pathways remain untargeted by the existing treatments. Research effort to identify 
previously unknown pathogenic pathways is therefore critical in the development of 
novel therapeutic strategies that would overcome limitations of current treatments for 
heart failure. 
Cardiac hypertrophy is an integral part in the pathogenesis of heart failure 
Heart failure is a complex condition with multiple etiologies. Major risk factors 
found in large epidemiological studies include male sex, age, diabetes, and obesity. 
Heart failure is often the terminal progression of many cardiovascular conditions. 
Hypertension, ischemic heart disease, cardiomyopathy, and valvular disease can all 
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lead to heart failure. Cardiac hypertrophy, or the enlargement of the heart, is a 
condition frequently associated with these diseases, and is often an integral part of the 
pathogenesis in the development to heart failure. The heart is a muscular organ with 
90% of its mass made up by cardiomyoctyes. As in all muscle, the heart undergoes 
hypertrophic response in reaction to increased load. Cardiac hypertrophy can be 
divided into two categories depending on the underlying cause. Physiologic 
hypertrophy follows stimuli such as exercise training and pregnancy, is reversible and 
does not progress to heart failure. In contrast, pathologic hypertrophy results from 
cardiac insults such myocardial infarction, cardiomyopathy, and hypertension. In 
these cases the contractile property of the myocardium is impaired by the underlying 
conditions, and the heart must compensate to maintain cardiac output via hypertrophic 
response. Cardiac hypertrophy, in turn, leads to further diastolic and systolic 
abnormalities that degrade cardiac output. As a result, pathologic hypertrophy does 
not usually undergo remission and progresses into heart failure if left unmanaged. 
Molecular basis of cardiac hypertrophy 
Cardiac hypertrophy in response to pathological stimuli involves a complex 
network of molecular sensors, signal transducers, transcription factors, and a host of 
downstream target genes (reviewed in 19). Hypertrophic signals such as paracrine 
growth factors and physical stretching of the myocytes are sensed by cell surface 
receptors. These include integrin, a transducer of mechanical stress, endothelin-1 
receptor, adrenergic receptor, EGF receptor, IGF1 receptor, and thyroid hormone 
receptor. These receptors are targets of some of the most successful drugs to treat 
heart failure such as ACE inhibitors and β-blockers. Nuclear receptors, such as the 
thyroid hormone receptor, can translocate into the nucleus upon activation. Signals 
from other receptors rely on signal transduction pathways to reach the transcription 
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factors in the nucleus. These pathways often begin with the disassociation of activated 
g-proteins from the receptors. The g-proteins, in turn, pass the signal through a 
network of kinases to the transcriptional and translational machineries to produce the 
hypertrophic response. Intracellular calcium is another critical component of the 
signal transduction leading to cardiac hypertrophy. Calcineurin, for example, is a 
phosphatase that is activated by sustained increase in the intracellular calcium level 
20,21. When activated, calcineurin dephosporylates a number of proteins, including 
transcription factor NFAT. In the nucleus, activated transcription regulators such as 
NFAT, Mef2, and HDACs are recruited to modulate the expression of target genes 
that induces various aspects of the hypertrophic response. These may include 
switching from fatty acids to glucose as fuel 22, reactivation of fetal genes 23, 
increased protein synthesis 24, increased apoptosis 25,26, and cell growth. 
Relevant mouse models of cardiac hypertrophy 
Transverse aortic constriction model (TAC) Since its invention in 199127, 
transverse aortic constriction in rodents has been a widely adapted model of pressure 
overload induced cardiac hypertrophy. In this model, a suture band is placed around 
the transverse aorta using microsurgical techniques. The degree of aortic banding is 
carefully controlled to produce a stenosis that results in a pressure gradient averaging 
around 40mmHg, doubling the normal range, in the aorta proximal to the suture band 
27. This increases the afterload that the heart must pump against. The heart mitigates 
the increased afterload either by increasing the ventricular wall thickness or by 
increasing the ventricular diameter in accordance with the Law of LaPlace 28. TAC is 
highly effective in inducing cardiac hypertrophy. Typically, differential gene 
expressions in the TAC mice compared to that in the sham operated littermates can be 
measured mere hours following the operation while increased cardiac mass can be 
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observed less than a week post operation. TAC, however, is not without drawbacks. 
An experienced animal surgeon is required to maintain high consistency and low 
mortality in TAC operations. 
Calcineurin overexpression model Calcineurin transgenic (CnA-Tg) mice21 
express a constitutively active form of calcineurin driven by a αMHC promoter, 
thereby producing a high level of activated CnA protein in the heart. Calcineurin, as 
described earlier, catalyzes the dephosphorylation of cytoplasmic NFAT in response 
to sustained increases in intracellular calcium level. Dephosphorylated NFAT 
translocates to the nucleus and activates a transcription program that is sufficient to 
cause cardiac hypertrophy. CnA-Tg mice thus develop extensive cardiac hypertrophy 
as early as five weeks of age. Similarly to the TAC model, the CnA overexpression 
model is widely used in studies of cardiac hypertrophy. The CnA overexpression 
model offers several advantages over the alternative. Since it is a genetic model, there 
is a high degree of consistency in the cardiac hypertrophy developed in the CnA-Tg 
mice. The extent of cardiac hypertrophy in these mice is often greater than what can 
be achieved in surgical models. Lastly, there are no specialized staff and 
instrumentation requirements to utilize the CnA-Tg mice in a study.  
Role of Nkx2-5 in cardiac hypertrophy and heart failure 
Nkx2-5 is a cardiac-specific transcription factor required for normal heart 
development. Mutations of human NKX2-5 are associated with inherited congenital 
heart defects (CHDs) 29,30. In mice, homozygous deletion of Nkx2-5 halts heart 
development and is lethal to the embryo at E9-10. Heterozygous deletion of Nkx2-5 
(Nkx2-5+/-) leads to a less severe phenotype. Nkx2-5+/- mice in C57 background 
survive birth but carry a risk for conduction defects and CHDs 31. In the embryo, 
Nkx2-5 expression first appears in the progenitor cells (in the heart field) specifying 
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cardiac cell fate. Nkx2-5 expression persists through heart development and into the 
postnatal adult heart 32. There is little literature describing the role Nkx2-5 plays in the 
adult heart. Nkx2-5 is up-regulated in animal models of cardiac hypertrophy 33 and, 
presumably, is involved in the development of the hypertrophic response. 
Experimental evidence, however, does not converge on a unified paradigm of how 
Nkx2-5 modifies the hypertrophic process. Transgenesis of dominant negative 
Nkx2-5 in the adult mice leads to myocyte degeneration and increases the severity of 
the detrimental effect of injected toxins on the heart 34,35. Similarly, conditional 
deletion of Nkx2-5 in post-mitotic mouse hearts results in conduction and contraction 
defects in the heart 36, although the severity of the phenotype decreases as the age of 
the mice increases when the deletion is triggered. In contrast, overexpression of 
wild-type Nkx2-5 using a αMHC promoter leads to the development of a conduction 
defect and heart failure 37,38. These conflicting results suggest that the role for Nkx2-5 
in the adult heart may be highly context-dependent. Further experiments where 
Nkx2-5 level is minimally perturbed may be necessary to disambiguate the function 
of Nkx2-5 in the postnatal heart. 
Transcriptional regulation and expression profiling 
Transcriptional is a fundamental mechanism underlying the causality of an 
organism’s inherent genotype and its observed phenotype. At the simplest level, 
transcription factors occupy transcription factor binding sequences (TFBSs) upstream 
of a given gene to promote mRNA synthesis by basal transcriptional machinery. 
Several mechanisms to modulate gene expression arise even within such a simple 
model of transcription. Protein-DNA interactions between transcription factors and 
TFBSs are governed by thermodynamics. As a result, variations in TFBS sequence 
identity directly affect the dynamics of transcription factor-DNA complex formation. 
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Other properties of TFBSs, such as distance, orientation, and phase on the double 
helix relative to a transcription start site can each influence interactions between 
transcription factors and transcriptional machinery. In addition, transcription factors 
may exert activating or suppressing effect. In mammalian cells, transcriptional 
regulation is far more complex than the above model. A typical mammalian gene is 
served by many transcriptional factors whose TFBSs are found anywhere from the 
introns of the gene to hundreds of kilobases away from the transcriptional start. 
Promoter/enhancer sequences can be covalently modified to vary their availability to 
transcription factors. Transcription factors are also subject to positive or negative 
regulation from upstream regulators, co-factors, or ligands, either by physical 
interaction or chemical modification. Furthermore, nascent mRNAs can be stabilized 
or degraded via covalent modification or microRNA regulation. Together these 
mechanisms form a regulator network to ensure robust temporally- and 
spatially-specific expression of genes at appropriate levels. 
 
In normal development, as well as in pathogenesis of diseases, genes are 
differentially regulated through modifications in transcriptional regulatory networks. 
High-throughput experimental methods such as oligonucleotide microarray and, more 
recently, parallel sequencing of cDNA (RNA-Seq), have been developed in the past 
15 years to simultaneously quantify large number of mRNA transcripts. The 
discipline of bioinformatics was created to manage datasets from these experiments 
where the raw output has grown from mere megabytes, in the early generations of 
microarrays, to hundreds of gigabytes in the latest RNA-Seq platform. As these 
methods became accessible and increasingly ubiquitous in non-specialized 
laboratories, a gap between the ability to generate data and the expertise to analyze 
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data has widened. Massive amount of data are deposited in open-access public data 
repositories such as Gene Expression Omnibus but publications resulting from 
meta-analyses of public datasets have been few in comparison. A computational 
framework that is easy to implement, robust against outliers, insensitive to variations 
in data processing practices by originating labs, and flexible to accommodate addition 
of orthogonal data would promote utilization of high-throughput datasets and 
maximize value of research investment. 
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Chapter 2: Gene discovery by non-parametric analysis of massively pooled, 
public expression microarray data 
 
Iuan-bor D. Chen1, Vinay K. Rathi1, Diana S. DeAndrade1, Maria Efimova1, Patrick 
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ABSTRACT 
The vast trove of expression profiles in the Gene Expression Omnibus (GEO) 
contains biological gems, but their mining poses formidable challenges not least 
because data normalization is a complex problem. We present a simple, 
non-parametric solution. Datasets based on the same microarray platform are 
classified into two or more experimental groups. No pre-processsing of expression 
data is necessary except for ranking probesets within each microarray in order of 
signal intensity. The ranks of a probeset are then ranked across the microarrays that 
comprise the experimental groups. Rank sum tests determine relative differences in 
gene expression. Applied to the thousands of profiles of mouse tissues in GEO, the 
method could define tissue-specific gene expression patterns across a wide dynamic 
range. This permitted the accurate prediction of genes specifically relevant to the 
function of an organ as well as the physiologic functions of an organ. Reasoning that 
genes that perform a function are more specifically expressed in tissues that perform 
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the function than other tissues, we designed bioinformatic screens for transcription 
factors that regulate brown adipocyte gene expression. Comparing the heart and 
brown adipose tissue (BAT), the two most mitochondrial-rich tissues in the body, to 
white adipose tissue (WAT), we predicted and validated a novel function for the 
transcription factor Esrrg in the induction of BAT genes in white fat. Because the 
heart and other tissues that express Esrrg do not express BAT genes, we hypothesized 
that an adipocyte cofactor is required with Esrrg for BAT gene expression. By 
comparing WAT and BAT to the heart, brain, kidney and skeletal muscle, we 
discovered that an isoform of the transcription factor Srebf1 could induce BAT genes 
in a muscle cell culture model. The results illustrate how our computational strategy 
can make genomic data mining fruitful and more accessible to a larger community. 
AUTHOR SUMMARY 
Microarrays are a popular means to quantify the expression of thousands of 
genes in a sample simultaneously. An experiment generates more data than an 
investigator could ever interpret. The Gene Expression Omnibus (GEO) was hence 
established so that others could glean additional insights from functional genomic 
data. Data mining, however, typically requires a computational infrastructure that few 
laboratories have because the preparation of heterogeneous datasets for conventional, 
parametric statistical tests is complex. Given the huge number of GEO profiles for 
virtually every cell and organ in the body, we show that a non-parametric statistical 
approach is simpler and yet sufficiently powered to discover genes and biological 
patterns. In proof-of-concept analyses we identified many genes known to be 
specifically expressed in various organs and relevant to their function. Furthermore, 
we could accurately predict the physiologic functions of an organ based on its list of 
genes ranked by their specificity of expression. To prove the utility of our method 
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prospectively, we designed bioinformatic screens and discovered two transcription 
factors that regulate gene expression in brown fat. The more accessible computational 
strategy can thus streamline the notoriously labor-intensive process of gene discovery 
by harnessing the collective effort of the biomedical research community. 
INTRODUCTION 
Transcriptional profiling with microarrays is a popular means to explore gene 
expression patterns. Consequently, a massive amount of data exists for virtually all 
the tissues in the body. Submission of the data to public databases like the Gene 
Expression Omnibus (GEO) is promoted so that secondary analyses can increase the 
scientific return on a collectively huge investment.39 Compelling discoveries support 
this intent,40-42 but typically only the contributors ever analyze the data. 
Non-standardized data filtering, scaling and normalization can hinder the replication 
of the original analytical results. Differences in sample preparation, hybridization, 
scanning, and image processing can confound the reproducibility of an experiment, 
which complicates the pooling of data across studies.43,44 
All these issues are problematic because conventional statistical analyses of 
microarray data are parametric. Data normalization, which can be vexing, is necessary 
to assure a uniform probability distribution. We reasoned that a non-parametric 
approach based on rank sum statistics could facilitate secondary analyses of 
aggregated microarray datasets. Several properties of rank sum statistics make it ideal 
to circumvent difficult problems with microarray data. First, the test is insensitive to 
the underlying distribution of the observations, obviating the need for normalization. 
Second, the results are robust against outliers and missing data because the test omits 
some of the variance information contained in the datasets. The resulting loss of 
statistical power can be offset by large sample sizes. Finally, rank sum statistics 
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requires relatively little computational power and is amenable to parallelization. 
To demonstrate the utility of the approach, we defined the tissue-specificity of 
gene expression patterns across the genome for multiple organs by a meta-analysis of 
GEO datasets based upon the Affymetrix Mouse Genome 430A 2.0 (MG430Av2) 
microarray. In the past, genome-wide, tissue-specific gene expression patterns have 
been determined by counting ESTs, which biases against rare transcripts.45,46 More 
recently, tissue-specific gene expression patterns have been surveyed using a few 
microarrays per organ, which limits the power to detect differences.47-51 In contrast, 
the results of the rank sum method suggest that the approach is robust and sensitive 
across a wide dynamic range of expression because the analysis draws from up to 
hundreds of samples per organ and thousands for comparison between tissues. 
A useful product of the method is the ranking of genes from most specifically to 
most counter-specifically expressed in an organ. The term “counter-specific” is used 
instead of “repressed” or “suppressed” so as not to imply an active regulatory 
mechanism. Organs that perform a common function likely employ the same genes. 
The genes are probably more specific to organs that perform the function than 
elsewhere. This premise logically suggests bioinformatic screens for genes based on 
threshold criteria for tissue specificity in various organs. The threshold criteria are 
determined by set logic, prior knowledge, or both. 
We thus developed bioinformatic screens for genes that regulate brown 
adipocyte gene expression. Under normal conditions, uncoupling protein 1 (Ucp1) is 
expressed predominantly in brown adipose tissue (BAT) but can be induced in the 
white adipose tissue (WAT) of animals exposed to the cold.52-54 Ucp1 uncouples 
mitochondrial oxidative phosphorylation to generate heat instead of ATP. BAT shares 
the abilities with WAT for fat uptake and with cardiac and skeletal muscle for energy 
16 
 
production via abundant mitochondria. The transcriptional coactivator, Prdm16, is 
essential for the specification of BAT from a pre-myogenic precursor in the embryo 
and the induction of BAT in adult WAT.55-59 Other genes are known to regulate BAT 
gene expression.60 Additional genes might be found by comparing tissue-specific 
gene expression patterns in WAT, BAT and mitochondrial-rich organs like the heart. 
Through a series of bioinformatic screens and biologic experiments we identified 
estrogen-related receptor gamma (Esrrg) and sterol regulatory element binding 
transcription factor 1 (Srebf1) as transcriptional regulators of Ucp1 and other BAT 
markers. 
RESULTS 
A non-parametric algorithm ranks genes by their tissue specificity of expression 
Although expression microarrays are perceived to be insensitive to differences 
among genes expressed at low levels, the non-parametric method could rank the 
tissue-specificity of gene expression across a wide dynamic range. First, the 
fluorescence rank of a gene, as represented by a probeset, was determined in order of 
decreasing brightness for each microarray in the pooled dataset. Second, the 
expression rank of a gene was determined by ranking the fluorescence ranks across all 
the microarrays, which in turn were classified as being from the tissue of interest or 
not. Third, we performed rank sum tests of the expression ranks for every gene in the 
two microarray groups. The analysis generates a Z-score that lends itself to 
genome-wide ranking of genes (Supplementary Table 2.1). Negative or positive 
Z-scores correspond to genes specifically or counter-specifically expressed in the 
tissue compared to all others. The tissue-specificity rank of each gene derives from 
ranking the Z-scores. The analyses were performed on datasets from a single 
microarray platform so that cross-platform differences in probeset performance would 
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not confound the fluorescence rank relationships between genes (Fig. 2.1). Examples 
of genes that are specific, counter-specific or neither in the heart follow. 
The transcription factor Nkx2-5 and cardiac actin isoform Actc1 are expressed 
almost exclusively in the heart.32,61 Consistent with their respectively low and high 
levels of expression, their median fluorescence ranks are 3542 and 15 among the 
45101 probesets in 175 profiles of postnatal murine hearts and 25449 and 25485 in 
2270 non-heart arrays (P < 1 X 10-101 for both genes; Fig. 2.1b). From these data were 
calculated the specificity ranks. Nkx2-5 and Actc1 are ranked 89 and 11 in the heart 
but much lower in non-heart tissues (Fig. 2.1c). 
At the opposite extreme, the fatty acid elongation protein Elovl5 is expressed at a 
much lower level in the heart than elsewhere.62 The median fluorescence ranks of the 
gene are 4485 and 1404 in the heart and non-heart arrays (P < 1 X 10-101; Fig. 2.1b). 
The tissue-specificity rank of Elovl5 in the heart is 44970. The Z-score is large and 
positive, consistent with counter-specific expression of the gene in the heart (Fig. 
2.1c). 
The ribosomal subunit Rplp0, also known as Arbp or 36B4, is expressed at 
comparable levels in diverse tissues.63 The median fluorescence ranks of Rplp0 were 
179 and 221 in the heart and non-heart arrays (P = 1; Fig. 2.1b). The gene has a 
tissue-specificity Z-score near zero in most organs, reflecting its ubiquitous and 
consistent level of its expression (Fig. 2.1c). 
Rarely is a gene expressed exclusively in a single organ. A limited pattern of 
expression can still be relatively tissue-specific. The algorithm provides a means to 
judge relative specificity, as illustrated by the comparison of actin isoforms expressed 
in skeletal muscle. Skeletal alpha-actin, Acta1, comprises ≥95% of the sarcomeric 
actin in skeletal muscle, whereas Actc1 is a minor fraction.61 Acta1 and Actc1 have 
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specificity ranks of 68 and 1031 in skeletal muscle, but Actc1 is still more specifically 
expressed in muscle than other tissues except the heart (P < 1 x 10-34; Fig. 2.1c). 
Genome-wide rankings of tissue-specific expression offer insight into gene and 
organ function 
The expression pattern of a gene can offer insight into its function. Several 
observations suggest that our algorithm could offer similar insights. First, the 
tissue-specificity rank of a gene in each organ appears to correlate well with a 
function specific to the organ, as illustrated by the 10 transcription factors deemed 
most specific in 15 tissues (Fig. 2.2). On average, mutation or knockout of ~6 of the 
10 transcription factors is associated with a human disease or mouse phenotype 
related to the function of the gene in the tissue. Of course, tissue-specific genes that 
do not have a known mutant phenotype could still have a function. For example, 
myelin transcription factor 1-like (Myt1l) is the third most brain-specific transcription 
factor and with two other transcription factors can convert fibroblasts directly into 
neurons (P = 4 x 10-274; Fig. 2.2, Supplementary Table 2.1). 64 The two, Pou3f2 and 
Ascl1, are also highly brain-specific (P < 1 x 10-107 and < 1 x10-17. The least 
significant statistic of the two probesets that represent each gene is presented.)  
The repertoire of genes expressed by an organ determines its functions, which 
suggests that the tissue-specificity ranks of genes could be adapted to predict organ 
functions. Based on the Gene Ontology (GO) annotations for each gene, we 
performed a rank sum analysis of biological processes according to their distribution 
on the tissue-specificity rank list of an organ. Perusal of the analyses shows that the 
specialized functions of an organ can be predicted from pooled microarray data (Fig. 
2.3, Supplementary Table 2.2). Closer inspection suggests that additional insights may 
be gleaned. For example, the testis and ovary produce gametes and sex hormones. 
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Consistent with their shared functions, there is substantial overlap of the statistically 
significant genes and biologic processes in the two gonadal organs (Fig. 2.2, 2.3). The 
analyses can even suggest less obviously shared genes or functions. Genes and GO 
terms related to immunity are expected for the spleen and thymus, but they are also 
enriched in the intestine, lung and skin, thus highlighting their common function as a 
barrier against pathogens (Fig. 2.3, Supplementary Tables 2.1 and 2.2). 
Esrrg regulates brown adipocyte gene expression in white fat 
The prior analyses of pooled microarray data revealed known tissue-specific 
genes and biologic processes. We next tested predictive utility based upon the premise 
that tissues that perform a common function utilize the same genes that are more 
specifically expressed in said tissues. We developed a bioinformatic screen for genes 
that could induce brown adipocyte gene expression in white adipose tissue while 
considering two key facts. First, Prdm16 is a critical determinant of the brown fat 
phenotype.59 Second, the heart and BAT are the most mitochondrial-rich tissues in the 
body, whereas WAT is mitochondrial poor. We defined genes whose expression is 
more or as specific to BAT and heart and more or as counter-specific to WAT than 
Prdm16 in each tissue. The screen yielded 104 probesets, representing 97 unique 
genes (Fig. 2.4a, Supplementary Table 2.3). The set is enriched for genes whose 
products localize to the mitochondria (51% versus 9.3% of all genes on the 
microarray, P = 3.07x10-16; Fig. 2.4b). In addition, 11% of the genes are regulated 
directly or indirectly by the transcription factor Esrrg.65 which is also in the set, 
whereas <1% of all represented genes are (P = 6.38x10-7). The increased mRNA 
expression of Esrrg in BAT relative to WAT was verified by quantitative RT-PCR 
(Fig. 2.4c). 
These observations led us to examine the ability of Esrrg to induce mRNA 
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markers of brown fat in OP9 cells, a white adipocyte cell culture model.66 Transiently 
transfected Esrrg could up-regulate the expression of the BAT markers Ucp1, Cidea, 
and Pcg-1α in differentiated OP9 adipocytes, while down-regulating the WAT marker 
resistin (Fig. 2.4d, 2.4e). Esrrg had no effect in undifferentiated OP9 pre-adipocytes, 
suggesting the requirement for an adipocyte-specific co-factor (Fig. 2.4d). 
BAT gene expression can be induced in white adipocytes by the Pparg agonist 
rosiglitazone.[34-36] Rosiglitazone similarly induced BAT markers as well as Esrrg 
in differentiated OP9 adipocytes (Fig. 2.4f). To determine whether induction depends 
upon Esrrg, we applied 4-hydroxytamoxifen (4-OHT), an Esrrg antagonist.67,68 The 
drug suppressed the rosiglitazone-mediated induction of Ucp1 and Cidea (Fig. 2.4f). 
Esrrg was likewise suppressed, which suggests either that Esrrg regulates its own 
expression in a positive feedback loop or that 4-OHT acts on another target that 
regulates Esrrg expression. Unfortunately, efforts to transfect OP9 cells with shRNA 
constructs, as an alternative means to knock down Esrrg activity, were unsuccessful. 
Mice subjected to the cold induce BAT genes in WAT. After housing for three 
days at 4oC, Ucp1 and other BAT markers were up-regulated up to ten-fold in the 
WAT. The up-regulation was abrogated by 4-OHT, which is consistent with a role for 
Esrrg in the induction of BAT in WAT (Fig. 2.5a). Visual inspection during gross 
dissection suggested that there was more intrascapular BAT after cold exposure, but 
the expression of Ucp1 and other markers was only slightly upregulated or unchanged 
(Fig. 2.5b). 4-OHT may not inhibit Ucp1 expression in BAT because Esrrg is 
expressed an order of magnitude higher than in WAT (Fig. 2.4c). Treated mice 
maintained normal body temperature while housed in the cold, consistent with the 
maintenance of Ucp1 expression in BAT. 
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Srebf1 induces brown adipocyte gene expression in cultured myoblasts 
Esrrg induces BAT gene expression in adipocytes, but Esrrg is also highly 
expressed in mitochondrial-rich tissues that have no Ucp1 (Fig. 2.6a.). White 
adipocytes may possess a cofactor that renders them competent to express BAT 
markers in the presence of Esrrg. A hypothetical cofactor should be expressed more 
specifically in white and brown adipose tissue than mitochondrial-rich organs. 
Prdm16 is probably not the cofactor, as the brain, heart and kidney express the gene, 
albeit at lower levels than in BAT (Fig. 2.6a). A bioinformatic screen was designed 
for genes that have negative tissue-specific Z-scores in WAT and BAT and positive 
Z-scores in brain, heart, muscle and kidney. The screen yielded 614 annotated 
probesets representing 564 unique genes, including 53 transcriptional regulators 
(Supplementary Table 2.4). Srebf1 was selected for further analysis in a muscle cell 
culture model because its expression pattern closely resembled the criteria for the 
hypothesized Esrrg co-factor (Figure 2.5b). Of two alternatively spliced forms, 
Srebp-1a and -1c, Srebp-1c was chosen for transfection because it is the predominant 
isoform in white and brown adipocytes.69 
Transfection of C2C12 myoblasts with Srebp-1c significantly induced the 
expression of Ucp1, other BAT markers and Esrrg (Fig. 2.6c). If Srebp-1c and Esrrg 
act together to induce brown adipocyte gene expression, then inhibition of Esrrg 
should repress the induction in C2C12 cells by Srebp-1c. Consistent with this 
hypothesis, 4-OHT abrogated the up-regulation of BAT markers by Srebp-1c, just as 
it did in OP9 cells and in the WAT of cold-exposed mice. RNAi knockdown of Esrrg 
likewise repressed the induction of BAT markers by Srebp-1c, whereas a control 
shRNA had no effect. Srebp-1c had no effect on the expression of the 
myocyte-specific marker tropomyosin 1 alpha (Tpm1) (Fig. 2.6c).  
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DISCUSSION 
Nature does not readily reveal the inner workings of life. Biologists expend great 
effort on screens to discover genes and experiments to elaborate gene function. We 
suggest that in some cases the total effort might be distributed across the larger 
community. Expression microarrays have become a commonplace tool, whereas 
statistical analyses seem increasingly complex. This asymmetry fosters the perception 
that data mining is accessible only to laboratories that have substantial bioinformatics 
support. Some complex problems do require sophisticated solutions, but a simple, 
non-parametric statistical approach to massively pooled, heterogeneous datasets 
uncovers a fertile middle ground. We apply the approach to provide a database that 
ranks the tissue-specificity of gene expression in multiple organs and evidence for the 
function of two transcription factors in BAT gene expression. 
Microarray data are typically normalized to remove variation that is not of 
biological interest. Normalization remains a challenging problem even when an 
experiment is well-defined.41,70 Normalization of heterogeneous, pooled datasets is 
immensely harder. Non-parametric statistics is suited for cases where the underlying 
distribution of data is uncertain and when large sample sizes are available. Despite the 
greater statistical power of parametric tests, rank sum tests applied to aggregated GEO 
datasets could clearly define tissue-specific gene expression patterns in a variety of 
organs. The large sample sizes afforded by GEO ensure the robustness of analyses 
against random and technical variation. Genes are detected across a wide dynamic 
range of expression, as shown by the identification of low-expressed transcription 
factors with organ-specific functions. Higher order biological patterns hidden in GEO 
are also detectable, as shown by the prediction of the specialized functions of organs. 
In addition to demonstrating the utility of the strategy, the tissue-specificity rank 
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lists for multiple organs may be useful in their own regard. For example, given a 
chromosomal interval determined by genetic linkage or association, one may ask 
whether any gene within the locus is expressed in an organ relevant to the phenotype. 
More broadly, the statistical strategy should be amenable to any biological question 
that can be addressed by comparison of microarray samples classified into two or 
more groups. The resulting list of ranked genes can inform experimental priorities, as 
shown by implication of Esrrg and Srebf1 in BAT gene expression. 
A good screen should be simple and fruitful. Mechanistic questions remain 
regarding the role of Esrrg and Srebf1 in the determination of the BAT phenotype, but 
the experimental results prospectively demonstrate the yield of a bioinformatic 
strategy based upon simple statistical analyses of public microarray data. Other genes 
that were identified in the same screens as Esrrg and Srebf1 likely have relevant 
functions. For example, Pgc-1α was identified in the screen for genes specific to the 
heart and BAT but not WAT. Originally cloned from a brown fat cDNA library, 
Pgc-1α is essential to mitochondrial biogenesis and BAT thermogenesis.71,72 In the 
screen for genes specific to BAT and WAT but not other mitochondrial-rich tissues, 
Tle3 was represented by two probesets along with Srebf1 and 51 other transcriptional 
regulators. Tle3 was recently discovered in a screen of 18,292 cDNA vectors to 
co-regulate adipogenesis with Pparg. Interestingly, Cebpa, a positive control in the 
cDNA screen, was likewise identified in the bioinformatic screen.73 
Obviously, no screen is perfect or all-encompassing. Sensitivity is limited by the 
design of the screen. For example, the present analyses would not identify 
ubiquitously expressed genes that regulate BAT gene expression. Specificity is a 
concern too, but seemingly false positive results could be genes that have functions 
implicitly included in a bioinformatic screen. Hence, the screen that yielded Esrrg 
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captured genes that perform mitochondrial functions, which is consistent with the 
high abundance of mitochondria in the heart and BAT. Despite the limitations, we 
suggest that they are outweighed by the relative simplicity of the non-parametric 
statistical approach and the consequent ease of extracting biological insights from 
GEO. Tapping into the collective labor that populated the public database, a research 
team could spread the herculean effort otherwise expended by them to elucidate a 
gene or biological function. 
METHODS 
Data acquisition and processing 
Via the GEO interface 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL1261), we downloaded 
4983 Affymetrix Mouse Genome 430A 2.0 microarray datasets (MG430Av2; 
Affymetrix, Inc., Santa Clara, CA; GEO platform accession GPL1261) in SOFT 
format. A custom Perl script parsed the SOFT file and assigned a source organ to each 
sample by matching a set of keywords for each organ to the sample source and the 
submitter’s description fields. Computer-generated organ designations were manually 
confirmed by IDC and PYJ. An overview of the microarray collection is shown (Fig. 
2.1a). Of the 4983 microarrays in the collection, 2538 were excluded because the 
biological samples were of unknown origin, fetal in origin, cultured cell lines, or 
derivatized, e.g., a subpopulation of cells purified from an organ, resulting in a set of 
2445 microarray datasets used in the tissue-specific gene expression analysis. 
Probeset annotations (release 30) in .csv format were downloaded from the 
Affymetrix NetAffx portal (www.affymetrix.com). 
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Statistical algorithm 
To detect differential gene expression between two groups consisting of a total of 
m samples run on the same microarray platform, the meta-analysis algorithm first 
converted absolute fluorescence values (i.e., VALUE column from the SOFT 
formatted file) within each microarray sample into fluorescence ranks from 1 to n in 
order of decreasing brightness, where n is the number of probesets represented on the 
microarray (Fig. 2.1b). For samples with fewer than n fluorescence values reported, 
the fluorescence ranks were scaled to range from 1 to n. For each of the n probesets, 
the algorithm ranked the fluorescence rank values in descending order across the m 
samples to determine expression ranks from 1 to m. A Wilcoxon rank sum test was 
then applied to the expression rank values for the two groups being compared to 
generate a Z-score, where a greater absolute Z-score represents more significant 
differential expression between the two groups being compared. The sign of the 
Z-score indicates which of the two groups has higher relative expression of the gene 
as measured by the probeset. To assess tissue-specific expression, the samples from 
the tissue of interest are compared to all others that are not. The tissue-specificity rank 
of a gene was determined by ranking Z-scores generated by the rank sum tests from 
the most negative to the most positive; a lower Z-score reflects greater tissue 
specificity. 
Gene Ontology analysis 
Gene Ontology (GO) biological process terms associated with the probesets on 
the Affymetrix MG430Av2 microarray were extracted from the probeset annotation 
file. The tissue-specificity of a given GO term was determined by a rank sum test. 
Probesets from a tissue-specificity rank list for a particular organ were divided into 
two groups that were either annotated with the given GO term or not. The enrichment 
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of the annotated group toward the top or the bottom of the ranklist was described by 
the rank sum test Z-score and p-value. The enrichment of GO terms in a set of 
probesets identified in the bioinformatic screen for potential brown adipose tissue 
regulators was evaluated with GeneMerge.74 Significance thresholds were set at a 
false discovery rate of 5%. 
Cell culture 
The OP9 pre-adipocyte cell line was a generous gift from Dr. Paul Hruz 
(Washington University School of Medicine, St. Louis, MO). The OP9 culture was 
maintained and differentiated into adipocyte-like cells as previously described.66 The 
OP9 pre-adipocytes were transfected using Optifect (Invitrogen, Carlsbad, CA) as per 
the manufacturer’s instructions. Transfected OP9 adipocytes were cultured for an 
additional three days after transfection and differentiation before harvesting. In 
pharmacologic experiments, differentiated OP9 cells were incubated with the Pparg 
agonist rosiglitazone (10 µM in DMSO, Sigma Aldrich, St. Louis, MO) and/or Esrrg 
antagonist 4-hydroxytamoxifen (4-OHT; 10 µM in DMSO, Sigma Aldrich) for 48 
hours before harvesting. 
The C2C12 skeletal myoblast cell line was purchased from and maintained 
according to the protocol supplied by ATCC (Manassas, VA). C2C12 cells were 
transfected using Lipofectamine 2000 (Invitrogen) per the manufacturer’s instructions. 
The cells were maintained for an additional 36 hours after transient transfection 
before harvesting. In pharmacologic experiments, C2C12 cells were incubated with 
4-OHT at 10 µM for 48 hours before harvesting. 
Expression Plasmids 
A pcDNA3.1(-)-Met-Esrrg expression construct was a gift from Daniel Kelly 
(Burnham Institute for Medical Research, Lake Nona, FL). A pSV SPORT Srebp-1c 
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expression construct was purchased from Addgene (Cambridge, MA). Esrrg targeting 
(Target gene 26381) and control shRNA constructs from the RNAi Consortium 
library (Broad Institute, Cambridge, MA) were obtained via The Genome Institute at 
Washington University and the Children's Discovery Institute (St. Louis, MO). 
Animal Studies 
12-week-old female FVB/N mice were treated with intraperitoneal injection of 
4-OHT (25 mg/mL in sunflower seed oil and 10% DMSO) or vehicle once daily at 0.1 
mg/g/day. The mice were placed in a 4°C room six hours after the first injection. They 
received food and water ad libitum. The core temperature of each mouse was 
measured twice daily with a K-type thermocouple probe digital thermometer. 
Abdominal white adipose tissue and intrascapular brown adipose tissue were 
harvested after 72 hours of cold exposure. The experiments were approved by the 
animal studies committee at Washington University School of Medicine. 
RNA Isolation and Quantitative PCR 
RNA was isolated from the tissue samples using Trizol (Invitrogen), according to 
the manufacturer’s protocol. The precipitated RNA was resuspended in 175 µL of 
RNA lysis buffer from the SV Total RNA Isolation Kit (Promega, Madison, WI) and 
purified according to the manufacturer’s protocol. Total RNA from cultured cells 
were isolated with SV Total RNA Isolation Kit only. cDNA was synthesized from 2.5 
µg of total RNA using SuperScript VILO cDNA Synthesis Kit (Invitrogen) according 
to manufacturer’s protocol. 
Quantitative PCR of cDNA was performed in Cycler iQ system (Bio-Rad, 
Hercules, CA) or Mx3005P QPCR System (Stratagene, Santa Clara, CA) in a 40 µL 
reaction containing iQ SYBR Green Supermix (Bio-Rad) and PCR primers at a final 
concentration of 200 nM. Primer sequences were designed with the PerlPrimer or 
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obtained from PrimerBank.75,76 Primers were purchased from Sigma Aldrich or 
Integrated DNA Technologies (Coralville, IA). The primer sequences are available in 
the supplemental methods. Relative mRNA expression was calculated using the 
ΔΔ-Ct method and normalized to Hprt1. 
Student’s t-tests were used to compare groups in the qPCR studies. The data are 
reported as mean ± s.e.m. 
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FIGURES 
 
Figure 2.1: A non-parametric statistical approach defines tissue-specific gene 
expression patterns from massively pooled microarray datasets. (a) The tissue of 
origin for the 4983 Affymetrix MG430Av2 microarray samples downloaded from 
GEO and the number of samples for each tissue used in subsequent analyses are 
shown. (b) A gene, represented by a probeset, is ranked by its fluorescence intensity 
on a microarray for every sample in the collection. Top, fluorescence ranks for the 
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cardiac-specific transcription factor Nkx2-5 (red tracing) and cardiac actin isoform 
Actc1 (orange) are shown. Their fluorescence ranks are generally higher in cardiac 
microarrays, consistent with their cardiac specificity. Bottom, fluorescence ranks for 
the ribosomal subunit Rplp0 (green) and fatty acid elongation protein Elovl5 (blue) 
are shown. The fluorescence ranks of Rplp0 are equivalent in cardiac and non-cardiac 
samples, which is consistent with its known uniform expression in diverse tissues and 
its use as a reference or housekeeping gene for mRNA quantification. Elovl5 is 
expressed at low levels in the heart and likewise has generally lower fluorescence 
ranks in cardiac samples. The fluorescence ranks are plotted in reverse logarithmic 
scale. The non-cardiac portion of the tracings is compressed horizontally to facilitate 
the interpretation of the plots. (c) The tissue-specificity ranks of Nkx2-5, Actc1, Rplp0, 
and Elovl5 are shown for various organs in reverse logarithmic scale; higher points 
denote greater specificity. 
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Figure 2.2: The ten most specifically expressed transcription factors in 15 different 
tissues are listed. If several probesets represent transcription factor, the most 
significant probeset is shown. Genes were identified as transcription factors if their 
associated Gene Ontology terms included “0006355 regulation of transcription, 
DNA-dependent” or “0006350 transcription” and “0003677 DNA binding”. The 
official gene symbols and p-values derived from our tissue specificity rank sum 
analysis are shown. Filled boxes indicate the existence of human (H) or mouse (M) 
mutant phenotypes related to the function of the transcription factor in the organ. 
  
p-value H M p-value H M p-value H M p-value H M p-value H M
Hoxb9 9.6x10-24 Tbx20 1.4x10-104 Nr1i3 4.9x10-160 Wt1 1.3x10-42 Nr0b1 3.6x10-20
Tbx3 9.7x10-24 Atf6 6.0x10-103 Foxa3 1.9x10-156 Nr0b1 7.4x10-42 Dmrt1 4.6x10-20
Nr5a1 1.1x10-23 Nkx2-5 2.3x10-101 Ppara 1.6x10-145 Emx2 2.8x10-41 Wt1 2.3x10-19
Pbx3 1.4x10-23 Irx4 8.4x10-99 Nr0b2 7.0x10-145 Nr5a1 1.2x10-39 Lhx9 1.0x10-18
Phox2b 2.3x10-23 Gata4 1.7x10-95 Nr5a2 4.2x10-142 Dmrta1 2.0x10-39 Tcfl5 7.9x10-18
Phox2a 3.5x10-23 Mitf 1.3x10-92 Onecut2 1.4x10-140 Tshz1 7.8x10-38 Ing2 8.1x10-18
Tsc22d1 4.0x10-23 Hand2 1.1x10-91 Rxra 2.4x10-140 Nfxl1 1.1x10-37 Hoxd8 8.8x10-18
Hoxb6 4.7x10-23 Esrrb 6.6x10-89 Hnf4a 1.2x10-138 Zfp229 1.4x10-37 Zscan21 9.4x10-18
Lbx2 5.3x10-23 Heyl 6.7x10-86 Klf15 7.2x10-134 5730601F06Rik3.1x10-36 Tgif2 1.0x10-17
Ar 1.3x10-22 Mef2a 4.3x10-84 Nr1h3 9.2x10-134 Smad3 7.1x10-36 Sin3b 1.9x10-17
Ppargc1b 2.4x10-08 Elf3 8.8x10-111 Foxf1a 2.4x10-147 Grhl1 7.4x10-42 Myb 3.7x10-37
Ebf2 2.5x10-08 Vdr 4.3x10-100 Tbx2 2.3x10-145 Trp63 9.4x10-42 Gfi1 1.7x10-35
Cebpa 3.1x10-08 Klf5 1.0x10-88 Foxa1 8.1x10-145 Tcfap2a 1.1x10-41 Ikzf1 2.8x10-35
Pparg 3.3x10-08 Irf6 7.1x10-88 Elf5 4.6x10-144 Hr 1.0x10-40 Tcf7 3.6x10-34
Hoxa4 3.6x10-08 Esrra 1.5x10-87 Tbx4 6.3x10-141 Grhl3 1.3x10-40 Runx3 2.4x10-33
Txlng 5.0x10-08 Irf1 1.6x10-87 Epas1 5.3x10-139 Ovol1 1.6x10-40 E2f2 2.5x10-33
Thra 6.1x10-08 Hnf4a 2.8x10-87 Smad6 1.9x10-134 Tcfap2c 1.9x10-40 Ikzf3 5.1x10-33
Zbtb7b 6.8x10-08 Ovol1 3.3x10-87 Foxa2 3.1x10-131 Hoxc13 2.8x10-40 Aebp2 3.3x10-32
Rreb1 7.7x10-08 Irf7 2.2x10-86 Foxf2 5.0x10-131 Irx2 5.8x10-40 Csrnp1 2.2x10-31
Esrra 8.7x10-08 Nr1h4 3.9x10-84 Hopx 2.1x10-126 Nfe2l3 1.7x10-39 Nfkb1 6.8x10-31
Sub1 1.2x10-274 Hoxd10 1.6x10-52 Tbx15 2.0x10-57 Ikzf3 1.2x10-70 Dmrt2 1.2x10-35
Myt1l 4.0x10-274 Hoxd9 1.4x10-50 Myf6 1.3x10-55 Irf4 4.3x10-70 Pparg 3.3x10-35
Thra 4.7x10-262 Hoxa10 5.3x10-50 Six1 2.0x10-55 Fli1 4.5x10-69 Hoxc8 1.5x10-32
Ndn 2.6x10-259 Hoxd8 6.7x10-49 Myod1 3.1x10-55 Trim30 6.1x10-69 Ebf2 2.1x10-31
Arnt2 3.5x10-255 Sall1 3.3x10-48 Sox6 3.7x10-55 Runx3 1.2x10-68 Cebpa 3.7x10-30
Pou6f1 4.6x10-249 Hoxa9 4.7x10-48 Csda 4.8x10-54 Ikzf1 8.2x10-68 Hoxc5 4.7x10-30
Nr2f1 1.0x10-246 Pax8 4.4x10-46 E2f6 1.4x10-52 Stat4 1.1x10-67 Ebf1 1.7x10-29
Foxg1 1.9x10-243 Alx1 5.0x10-46 Tcea3 2.8x10-52 Nfatc3 1.6x10-67 Ar 3.1x10-29
Mapk8ip1 4.4x10-239 Emx2 1.9x10-44 Myog 2.8x10-52 Zfp53 1.8x10-67 Tcf15 4.4x10-28
Pou3f3 1.5x10-237 Foxc2 1.0x10-42 Lbx1 6.3x10-52 Stat1 2.2x10-67 Meox2 6.4x10-27
Brain Kidney Muscle Spleen WAT
Adrenal Heart Liver Ovary Testis
BAT Intestine Lung Skin Thymus
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Figure 2.3: The function of an organ can be predicted from the GO biological process 
terms assigned to genes ranked by their specificity of expression in the organ. 
Representative, significant functions for a number of organs are shown here with their 
GO accession number and P-value. Significance thresholds were defined by setting a 
false discovery rate to 5%. The full lists of GO terms are provided in the 
Supplementary Table 2.2. 
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Figure 2.4: Esrrg induces BAT gene expression program in white adipocytes. (a) 
Schematic representation of the bioinformatic screen. Left, the tissue specificity 
scores in BAT, WAT, and the heart are plotted for all 45101 probesets (gray) 
represented on the MG430Av2 microarray. The probesets (blue) that are more or as 
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specific to BAT and the heart and more or as counter-specific to WAT than Prdm16 
were identified. Right, the probesets are shown with Prdm16, Esrrg, and 
Esrrg-regulated genes in green, red, and yellow, respectively. (b) The subset is 
significantly enriched for mitochondrial genes and genes regulated by Esrrg. 
Significance thresholds were set by a false discovery rate of 5%. (c) Quantitative 
RT-PCR analysis of Esrrg mRNA in murine BAT and WAT (*, P = 0.023; n = 4). (d) 
Esrrg induces Ucp1 mRNA expression in differentiated but not undifferentiated OP9 
cells; GFP control transfections are shown for comparison (*, P < 0.05; n = 3). (e) 
Essrg induces additional BAT markers, Cidea, Pgc-1α, Pparg, and Prdm16, and 
suppresses the WAT marker Resistin in differentiated OP9 cells. (*, P < 0.05; n = 3). 
(f) The Pparg agonist rosiglitazone induces BAT markers in differentiated OP9 cells, 
an effect that is suppressed by the Esrrg antagonist 4-hydroxytamoxifen (4-OHT). 
Data are reported relative to vehicle-treated cells. (*, P < 0.05 versus vehicle-treated 
cells; #, P < 0.05 versus rosiglitazone-treated cells; n = 4). Error bars indicate s.e.m. 
BP, biological process. CC, cellular component. MF, molecular function. ND, not 
detected. 
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Figure 2.5: (a) Exposure of mice to the cold induces brown adipocyte gene 
expression in WAT. The Esrrg antagonist 4-OHT suppressed the effect of cold 
exposure. (b) 4-OHT did not suppress the cold-induced induction of Ucp1 in BAT 
possibly because Esrrg is expressed at higher levels in BAT than WAT. Fold changes 
are stated relative to the WAT or BAT of vehicle-treated mice housed at room 
temperature. (*, P < 0.05 with respect to vehicle treated mice at room temperature; #, 
P < 0.05 with respect to vehicle-treated mice exposed to the cold.) n = 6 animals per 
group. Error bars indicate s.e.m. 
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Figure 2.6: (a) Ucp1 is specifically expressed in BAT, whereas Prdm16 and Esrrg are 
expressed in various other tissues, suggesting that an adipocyte cofactor is necessary 
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for Esrrg to induce the brown adipocyte gene expression program (n = 4; ND, not 
detected). (b) Srebf1 is more highly expressed in the liver, WAT and BAT than other 
mitochondrial rich tissues (n = 4). (c) Srebp-1c induces the brown adipocyte gene 
expression program in C2C12 myoblasts. Induction depends upon endogenous Esrrg, 
as shown by inhibition or knockdown of Esrrg by 4-OHT or shRNA, respectively. A 
lacZ control shRNA construct had no effect on Srebp-1c induction of brown fat 
markers. The measurements are normalized to GFP-transfected cells. Transfections 
were performed in triplicate. Error bars indicate s.e.m. (*, P < 0.05 compared to 
GFP-transfected controls; #, P < 0.05 compared to Srebp-1c-transfected cells; n = 3). 
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Chapter 3: Nkx2-5 physically interacts with Egr1 to modulate pathological 
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Background: Nkx2-5 is critical in fetal heart development but the postnatal role for 
Nkx2-5 is less well known. 
Results: Nkx2-5+/- mice exhibit aggravated pathology and poor survival in cardiac 
hypertrophy. 
Conclusion: Nkx2-5 interacts with hypertrophy mediator Egr1 and suppresses the 
activation of Egr1 gene targets in cardiac hypertrophy.  
Significance: A novel pathogenic mechanism in cardiac hypertrophy is identified, 
demonstrating the utility of the bioinformatics presented. 
 
SUMMARY 
The cardiac-specific transcription factor Nkx2-5 is critical in embryonic heart 
development. In mice, Nkx2-5 null mutation is embryonically lethal. Nkx2-5 
heterozygous (Nkx2-5+/-) animals survive birth but have high rate of congenital heart 
defects. The postnatal role for Nkx2-5 is less well understood. The present study aims 
to delineate how Nkx2-5 functions in the adult heart by characterizing Nkx2-5+/- mice 
in the context of pathological cardiac hypertrophy. Nkx2-5+/- pups born without heart 
malformations were otherwise healthy and indistinguishable from wild-type 
littermates. In these mice, hypertrophic stimuli such as calcineurin overexpression 
(CnA-Tg) and transverse aortic constriction led to exacerbated hypertrophic responses 
and poor survival compared with wild-type littermates. Computational analyses in the 
proximal promoters of genes differentially regulated both in cardiac hypertrophy and 
Nkx2-5 haploinsufficiency under hypertrophic conditions revealed an enrichment of 
transcription factor binding sites for hypertrophy mediator early growth response 1 
(Egr1). In vitro, Nkx2-5 physically interacted with Egr1 and Egr1-specific suppressor 
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NGFI-A binding protein 1 (Nab1) to down-regulate Egr1-dependent transcriptional 
activation. NGFI-A binding protein 2 (Nab2) is a Nab1 paralog and a target of this 
regulation. An increase in Nab2 level reduced Nkx2-5- and Nab1-dependent 
suppression of Egr1 activity. In vivo, decreased Nab2 expression in Nab2+/-/CnA-Tg 
mice attenuated the hypertrophic response and improved survival in comparison to 
Nab2 WT/CnA-Tg littermates. Thus, Nkx2-5 can modulate cardiac hypertrophy 
through suppressing Egr1-dependent transcriptional activation in target genes such as 
Nab2. The computational method presented here is useful for discovering 
transcriptional regulatory pathways in physiological or pathological processes 
involving differential gene regulation. 
INTRODUCTION 
Pathological cardiac hypertrophy is an important sequela in heart conditions of 
diverse etiologies. In response to detrimental stimuli such as pressure overload, gene 
programs are activated in the heart to up-regulate protein synthesis, leading to 
increases in cardiomyocyte volume and cardiac mass. Cardiac hypertrophy is initially 
a compensatory mechanism but can progress to heart failure over time if left 
unmitigated 77. Transcriptional regulation is a critical mechanism in the pathogenesis 
of cardiac hypertrophy. The re-activation of genes normally restricted to the 
developing fetal heart, such as atrial natriuretic factor (ANF) and β-myosin heavy 
chain (Myh7), is a universal hallmark in pathological hypertrophic process 78. Nkx2-5 
is a cardiac-specific transcription factor with essential functions in cardiac 
development. Nkx2-5 has been shown to drive the expression of ANF, Myh7, and 
other cardiac hypertrophy marker genes 79, and is itself up-regulated in 
adrenergic-induced cardiac hypertrophy 33. In a study of heterozygous human NKX2-5 
mutation, several individuals haploinsufficient for Nkx2-5 presented with idiopathic 
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left ventricular hypertrophy 30. This led us to wonder whether the reduced NKX2-5 
level in affected individuals might lead to hypersensitivity to biomechanical stimuli 
that induce cardiac hypertrophy. We tested this hypothesis by characterizing the 
cardiac hypertrophic response in Nkx2-5+/- mice challenged with pathological surgical 
and genetic stimuli.  
Nkx2-5 exhibits a gene-dosage dependent developmental phenotype in the 
embryonic heart. In mice, a germline, homozygous knockout mutation in Nkx2-5 
leads to the arrest of cardiac development at the looped heart tube stage 79,80 and is 
embryonically lethal. Mice with a heterozygous deletion of Nkx2-5 (Nkx2-5+/-) survive 
birth, but the mutation is associated with an increased incidence of congenital heart 
defects (CHDs) such as atrial and ventricular septal defects (ASDs and VSDs) 31. 
Similarly, heterozygous mutations of NKX2-5 are associated with anatomic and 
conduction defects in human patients 30,81. Nkx2-5 expression persists into adulthood 
32, but the postnatal role of Nkx2-5 is less well defined. Because the genetic deletion 
of Nkx2-5 is embryonic lethal, alternative experimental strategies have been employed 
to elucidate the postnatal functions of Nkx2-5 34,82. Conditional deletion of Nkx2-5 
leads to degeneration in the conduction and contractile functions in the perinatal 
mouse model 36,82, suggesting that Nkx2-5 may be involved in the maintenance of 
cardiac function in healthy cardiomyocytes. The functional role of Nkx2-5 in 
pathological conditions is equally ambiguous. Overexpression studies of Nkx2-5 in 
mice have yielded mixed results, ranging from a hypertrophy-free phenotype to heart 
failure as early as 4 months of age 37,38. Transgenic mice expressing a dominant 
negative form of Nkx2-5, however, demonstrate both cardiac conduction defects and 
increased cardiac apoptosis when challenged with doxorubicin 34,35, suggesting that 
Nkx2-5 may be protective in the adult heart. The available experimental data thus 
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point to the involvement of Nkx2-5 in the pathogenesis of cardiac hypertrophy, 
although the precise role of Nkx2-5 in the development of cardiac hypertrophy was 
not examined directly. 
The Nkx2-5+/- mice expresses half the normal levels of Nkx2-5 mRNA and 
protein 81, which is a minimal perturbance in comparison to the alteration of mRNA 
levels seen in traditional overexpression and knock-out models. The characterization 
of the Nkx2-5 haploinsufficiency model should therefore lead to a more 
physiologically relevant model of how Nkx2-5 functions in the postnatal heart and 
how it affects the pathogenesis of cardiac hypertrophy. The present study identifies a 
putative mechanism underlying the Nkx2-5 dosage-dependent modulation of cardiac 
hypertrophy using unbiased computational analyses that allow for the identification of 
Nkx2-5 dosage-sensitive pathogenic pathways in cardiac hypertrophy in vivo. In 
addition, a novel interacting co-regulator of Nkx2-5 and a functionally relevant 
downstream target gene were identified as involved in the pathogenesis of cardiac 
hypertrophy. Lastly, the present study demonstrates the utility of our computational 
approach in identifying novel mechanisms of differential gene regulation in the 
pathogenesis of complex diseases. 
 
RESULTS 
 
Nkx2-5+/- mice demonstrate exaggerated cardiac hypertrophy in response to 
pathological stimuli 
Nkx2-5+/- mice express half-normal levels of Nkx2-5 mRNA and protein 81,83. 
The reduction in Nkx2-5 dosage increases the risk of congenital heart defects (CHDs) 
31 during fetal development. Nkx2-5+/- neonates without CHDs, however, grow into 
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healthy adults. Under basal conditions, adult Nkx2-5+/- hearts were indistinguishable 
from wild-type hearts in cardiac mass relative to body weight ratio (HW/BW, 4.3±0.1 
mg/g in Nkx2-5 WT/sham vs. 4.4±0.1 mg/g in Nkx2-5+/-/sham; P = 0.25; Fig. 3.1a). 
The phenotype associated Nkx2-5 haploinsufficiency became apparent only when the 
animals were subjected to adverse hypertrophic stimuli. Transverse aortic constriction 
(TAC) 27,84 performed on 8-10 week old wild-type mice resulted in an increase in 
HW/BW ratio compared with sham-operated littermates 10 days after surgery 
(4.3±0.1 mg/g in Nkx2-5 WT/sham vs. 5.5±0.2 mg/g in Nkx2-5 WT/TAC; P = 0.0004; 
Fig. 3.1a). After undergoing the same procedure, Nkx2-5+/- mice developed a 73% 
greater increase in HW/BW ratio compared with wild-type mice (28±5% increase in 
Nkx2-5 WT/TAC vs. 49±6% increase in Nkx2-5+/-/TAC; P = 0.01; Fig. 3.1a), 
suggesting that the development of appropriate cardiac hypertrophy in response to 
surgical perturbation is an Nkx2-5 dosage-sensitive phenomenon. 
A similar Nkx2-5 haploinsufficiency phenotype was observed in the 
calcineurin overexpression (CnA-Tg)21 model of cardiac hypertrophy. In 
five-week-old mice expressing normal cardiac levels of Nkx2-5, transgenic expression 
of calcineurin resulted in a doubling of heart weight in comparison to their 
non-transgenic (CnA-Ntg) littermates (HW/BW ratio 4.3±0.1 mg/g in Nkx2-5 
WT/CnA-Ntg vs. 9.0±0.2 mg/g in Nkx2-5 WT/CnA-Tg; P =0.0004; Figs. 3.1b and 
3.1c, Table 3.1). In Nkx2-5+/- mice, calcineurin overexpression tripled the heart 
weight relative to the non-transgenics (HW/BW ratio 4.3±0.1 in Nkx2-5+/-/CnA-Ntg 
vs. 13.3±0.5 in Nkx2-5+/-/CnA-Tg; P = 0.0001; Figs. 3.1b and 3.1c, Table 3.1). The 
hypertrophic response in Nkx2-5+/-/CnA-Tg mice was therefore twice that of Nkx2-5 
WT/CnA-Tg mice (110±5% increase in Nkx2-5 WT/CnA-Tg vs. 210±12% increase in 
Nkx2-5+/-/CnA-Tg; P = 0.0001; Figs. 3.1b and 3.1c, Table 3.1). An increase in lung 
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weight to body weight ratio, indicative of pulmonary edema, was observed in 
Nkx2-5+/-/CnA-Tg animals in association with the enhanced hypertrophic response 
(LW/BW ratio 6.0±0.1 mg/g in Nkx2-5 WT/CnA-Tg vs. 6.9±0.1 mg/g in 
Nkx2-5+/-/CnA-Tg; P =0.0001; Table 3.1). Similar to the TAC model, there was no 
difference in the heart weight to body weight ratio between Nkx2-5+/- and wild-type 
hearts under baseline conditions (4.3±0.1 mg/g in Nkx2-5 WT vs. 4.3±0.1 mg/g in 
Nkx2-5+/-; P =0.95 Figs. 3.1b and 3.1c, Table 3.1). Additional physiological 
parameters of Nkx2-5+/- mice under baseline and hypertrophic conditions are listed in 
Table 3.1. The replication of this Nkx2-5 haploinsufficiency phenotype in disparate 
cardiac hypertrophy models suggests that Nkx2-5-dependent modification of the 
hypertrophic response is independent of the types of hypertrophic stimuli. 
The aggravated hypertrophic response to calcineurin overexpression in 
Nkx2-5+/- animals compared with wild-type littermates can partially be attributed to 
the increases in individual cardiomyocyte size. Under non-hypertrophic conditions, 
the cross-sectional area of single cardiomyocytes measured from short-axis heart 
sections did not vary between Nkx2-5 WT and Nkx2-5+/- hearts (43.8±1.6 µm2 vs. 
42.3±1.2 µm2, respectively; P = 0.46; Fig. 3.1d). In the calcineurin overexpression 
model of cardiac hypertrophy, the cardiomyocyte cross-sectional area was increased 
by 57±7% in Nkx2-5 WT/CnA-Tg hearts compared with Nkx2-5 WT/CnA-Ntg hearts 
(P < 0.0001; Fig. 3.1d), whereas the cardiomyocyte cross-sectional area in 
Nkx2-5+/-/CnA-Tg hearts was >1.5 times greater than that in Nkx2-5+/-/CnA-Ntg hearts 
(P < 0.0001; Fig. 3.1d). This translates to roughly three times more growth in 
cross-sectional area of individual cardiomyocytes as a result of calcineurin 
overexpression in Nkx2-5+/- hearts in comparison with Nkx2-5 WT hearts. The 
enhanced cardiomyocyte hypertrophy observed in Nkx2-5+/- animals subjected to 
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hypertrophic stimuli was further corroborated by whole cell membrane capacitance 
recordings, which serve as a proxy measure of cardiomyocyte volume 85. 
Cardiomyocytes isolated from Nkx2-5 WT/CnA-Tg hearts exhibited 39±10% more 
capacitance than cardiomyocytes from Nkx2-5 WT/CnA-Ntg hearts (132.6±7.5 pF vs. 
184.9±7.1 pF, respectively; P < 0.0001; Fig. 3.1e). In Nkx2-5+/-/CnA-Tg hearts, the 
capacitance of cardiomyocytes was 60±10% greater than that of cells from 
Nkx2-5+/-/CnA-Ntg hearts (130.8±6.2 pF vs. 209.6±9.3 pF, respectively; P < 0.0001; 
Fig. 3.1e). Nkx2-5+/-/CnA-Tg cardiomyocytes thus hypertrophied 54% more than cells 
from Nkx2-5 WT/CnA-Tg hearts. The supernormal hypertrophic response in Nkx2-5+/- 
mice was additionally associated with impaired survival. Age of death as a result of 
calcineurin overexpression 86 in Nkx2-5+/-/CnA-Tg mice was significantly younger 
than that in Nkx2-5 WT/CnA-Tg littermates (196±8 days in CnA-Tg vs. 85±16 days in 
Nkx2-5+/-/CnA-Tg; P = 0.01; Fig. 3.1f). 
A subset of marker genes of cardiac hypertrophy was differentially regulated 
as a function of Nkx2-5 dosage under hypertrophic conditions. Quantitative RT-PCR 
analysis revealed an enhanced transition from a-myosin heavy chain (Myh6) to 
β-myosin heavy chain (Myh7) in Nkx2-5+/- hearts, where Myh7 expression level was 
elevated to twice the level seen in Nkx2-5 WT hearts in response to calcineurin 
overexpression (P = 0.01; Fig. 3.1g, bottom panels). In contrast, up-regulation of both 
ANF and BNP mRNA levels were not significantly altered in Nkx2-5+/- hearts in 
comparison to wild-type hearts under hypertrophic conditions (P = 0.44 and 0.16, 
respectively; Fig. 3.1g, top panels). Notably, the level of ANF mRNA, but not BNP 
mRNA, was decreased in Nkx2-5+/- hearts in comparison to wild-type hearts under 
baseline conditions (P = 0.01 and 0.08, respectively), suggesting that Nkx2-5 dosage 
sensitivity, in addition to being context-dependent, manifests differently for individual 
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genes. In a given cellular environment, such as that in the CnA-Tg heart, Nkx2-5 
haploinsufficiency only affects a subset of the molecular pathways involved in the 
hypertrophic response. 
Transcriptional profiling captures Nkx2-5 dosage-sensitive transcripts in cardiac 
hypertrophy 
A comprehensive survey of differential gene expression in Nkx2-5+/- and 
wild-type mice under basal and hypertrophic conditions would provide a foundation 
for identifying gene regulatory pathways that are sensitive to Nkx2-5 dosage in the 
context of cardiac hypertrophy. To this end, global gene expression profiling was 
carried out in the ventricular myocardium of wild-type, CnA-Tg, Nkx2-5+/-, and 
Nkx2-5+/-/CnA-Tg mice using oligonucleotide microarrays. In addition, a comparable 
dataset from a TAC experiment 87 obtained through the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) was included in the ensuing computational 
analyses to minimize the likelihood of discovering model-specific artifacts. 
Supplementary Table S3.1 summarizes the results from the microarray study. The 
complete dataset is available for download through the Gene Expression Omnibus via 
accession number (pending submission). Of the 12,422 total probe sets represented on 
the microarray, 1,885 were significantly different in hearts subjected to TAC in 
comparison to sham operated hearts at an ANOVA p-value threshold of 0.05 (Fig. 
3.2a). Of these probe sets, 727 were up-regulated and 1,158 were down-regulated. In 
the calcineurin overexpression model, significant differences in expression were 
detected between CnA-Tg mice and the non-transgenic littermates in 1,216 probe sets. 
Among these probe sets, 501 were up-regulated and 715 were down-regulated. 
Merging the two datasets produced 342 probe sets with significant differential 
expression in both the TAC and calcineurin overexpression models. 126 probe sets 
were up-regulated in both TAC- and calcineurin overexpression-induced cardiac 
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hypertrophy, including marker genes angiotensin I converting enzyme 1 (Ace) and 
BNP. Similarly, 162 probe sets were down-regulated in both models, including 
cardiac-specific homeodomain-only transcription regulator Hopx. The Gene Ontology 
(GO) biological process terms over-represented in the merged list of probe sets with 
significant differential expression in both models of cardiac hypertrophy are listed in 
Table 3.2. 
The comparison between Nkx2-5+/- and wild-type hearts under baseline 
conditions revealed significant differences in the expression of 1,219 probe sets. 
Within this group of probe sets, 422 probe sets indicated up-regulation and 797 probe 
sets indicated down-regulation. While Nkx2-5+/- adults had no discernable phenotype 
differences from wild-type adults under baseline conditions, GO analysis applied to 
the expression profiles of non-hypertrophic Nkx2-5+/- and wild-type hearts 
nevertheless identified biological process terms associated with the differences in 
gene expression at a false discovery rate of 5%, including “protein polymerization” 
and “protein biosynthesis”. The complete listing of GO terms associated with 
differential gene expression in Nkx2-5+/- hearts under baseline conditions is found in 
Table 3.2. Under hypertrophic conditions, comparisons among transcription profiles 
from Nkx2-5 WT/CnA-Tg and Nkx2-5+/-/CnA-Tg hearts revealed only 364 probe sets 
to be differentially expressed in a significant manner. Exactly one half of the probe 
sets in this grouping were up-regulated and the other half were down-regulated. The 
comparatively low number of differentially regulated genes suggests that the 
hypertrophic response as a result of calcineurin overexpression is not fundamentally 
different between Nkx2-5+/- and Nkx2-5 WT mice. GO analysis of these probe sets 
points to an enrichment of several biological processes related to heart function, but 
none reached statistical significance at a 5% false discovery rate. When the 364 probe 
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sets from this comparison were merged with the 342 probe sets differentially 
regulated in both TAC and CnA-Tg models, 33 probe sets were found at the 
intersection. These represented genes differentially expressed in cardiac hypertrophy 
whose expression levels were further modified as a function of Nkx2-5 dosage under 
hypertrophic conditions, presumably under the regulation of transcription regulatory 
pathways where Nkx2-5 has a dosage-dependent effect in the context of cardiac 
hypertrophy. 
Computational analysis suggests Nkx2-5 exerts influence on the Egr1 pathway 
The results of the transcription profiling experiments suggest that a reduced 
Nkx2-5 level affects a limited subset of genes involved in the hypertrophic response. 
However, the transcriptional pathways regulating this subset of genes may regulate 
other target genes, independent of Nkx2-5 dosage, in the pathogenesis of cardiac 
hypertrophy. We therefore devised a computational strategy to screen for transcription 
factors driving such regulatory pathways, using the entire complement of gene 
expression changes involved in the hypertrophic process and Nkx2-5 
haploinsufficiency (Fig. 3.2a). In this analysis, 394 experimentally determined 
mammalian transcription factor binding site (TFBS) profiles from the TRANSFAC 
database 88 were mapped to the proximal promoter sequences (from -2000bps to 
+500bps relative to annotated transcription start site) of each gene. The correlation 
between each TFBS’s presence in the proximal promoter with the differential gene 
expression in a given mouse model was then evaluated using a ranksum test. TFBS 
signatures associated with gene expression changes both in normal transition to 
cardiac hypertrophy (in TAC vs. sham and CnA-Tg vs. CnA-Ntg comparisons) and in 
the escalation of hypertrophic response as a result of reduced Nkx2-5 dosage (i.e. 
Nkx2-5+/-/CnA-Tg vs. Nkx2-5 WT/CnA-Tg comparisons) are indicative of Nkx2-5 
49 
 
dosage-sensitive transcriptional regulatory pathways active in cardiac hypertrophy. 
The comparison between Nkx2-5+/- and wild-type hearts was analyzed separately to 
identify Nkx2-5 dosage-sensitive pathways under baseline conditions. 
The TFBS screening results are shown in Supplementary Table S3.2, and 
summarized in Figure 3.2a. In the comparison between TAC and sham-operated 
hearts, 45 unique human and/or mouse TFBS profiles (P < 0.05) associated with 
differential gene expression (regardless whether up- or down-regulation) were 
identified from a total of 394 TFBS candidates. Similarly, 64 unique TFBS profiles 
were found to be associated with expression changes between the CnA-Tg hearts and 
the CnA-Ntg hearts. Neither of the two profiles representing Nkx2-5 TFBS was found 
in these two lists, suggesting that direct Nkx2-5 binding to the proximal promoters 
may not be a dominant mechanism in these models of cardiac hypertrophy. A further 
set of 50 unique TFBS profiles was found to be associated with differential gene 
expression in the comparison between Nkx2-5 WT/CnA-Tg and Nkx2-5+/-/CnA-Tg 
hearts, including one of the TFBS representing Nkx2-5 (M00240, P = 0.02). The 
above TFBS lists were merged to reveal three TFBS profiles corresponding to 
androgen receptor (Ar), BTB and CNC homolog 2 (Bach2), and early growth 
response 1 (Egr1) in the intersection of all three sets (Fig. 3.2a). The presence of these 
binding signatures in the proximal promoters is associated with differential gene 
expression in both TAC and calcineurin overexpression models and with the Nkx2-5 
dosage-dependent modification of gene expression in Nkx2-5+/-/CnA-Tg mice (Fig. 
3.2b). Of these transcription factors, Egr1 was singled out for further characterization 
in the present study because of its well-defined role in the pathogenesis of cardiac 
hypertrophy 89. 
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A separate analysis comparing Nkx2-5+/- and Nkx2-5 WT hearts identified 74 
unique TFBS profiles that are over-represented in the proximal promoters of 
differentially regulated genes in Nkx2-5 haploinsufficiency under baseline conditions 
(Fig. 3.2a and Supplementary Table S3.2). One of the two profiles representing 
Nkx2-5 was present in this list (M00241, P = 0.05), suggesting that direct Nkx2-5 
binding to the promoters may be necessary or sufficient in some of the Nkx2-5 dosage 
sensitive gene targets. Other members of this list include important transcription 
regulators in the postnatal heart, such as CREB, Hif1, Mef2, NFκb, PPAR, and SRF. 
A reduced Nkx2-5 level may affect transcriptional regulation in the target genes via a 
modulatory effect on these transcription co-regulators. Notably, Egr1 was not found 
in this set. Furthermore, only four unique TFBS profiles were found in the 
intersection of the Nkx2-5+/- sets under baseline or hypertrophic conditions 
(cumulative P for X ≤ 4 = 0.02, Fig. 3.2a). Taken together, the results from the 
Nkx2-5+/- TFBS screens suggest Nkx2-5 haploinsufficiency affects distinct 
transcriptional pathways in the heart depending on the pathological context. 
The TFBS screen in the hypertrophic hearts led to a hypothetical model where 
Nkx2-5 exerts a dosage-dependent effect on Egr1-dependent regulation of 
transcription in the pathogenesis of cardiac hypertrophy. Egr1 is an immediate-early 
transcription factor activated in cardiac hypertrophy 90,91 and a key mediator of the 
hypertrophic process. Saadane et al. demonstrated that homozygous deletion of Egr1 
attenuates hypertrophic response to TAC 89. Similarly, animals overexpressing 
Egr1-specific suppressor NGFI-A binding protein 1 (Nab1) responded to TAC with 
markedly reduced hypertrophy 92. In the calcineurin overexpression model, the 
expression level of Egr1 was elevated under hypertrophic conditions (P = 0.02; Fig. 
3.2c). The baseline expression and the up-regulation of Egr1 in cardiac hypertrophy 
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was unaffected by Nkx2-5 gene dosage (P = 0.51 under baseline conditions and P = 
0.37 under hypertrophic conditions; Fig. 3.2c). In comparison, the Nab1 expression 
level remained constant in cardiac hypertrophy and was neither a function of Nkx2-5 
dosage under baseline nor hypertrophic conditions (Fig. 3.2c). NGFI-A binding 
protein 2 (Nab2) is a Nab1 paralog with overlapping functional roles 93. Nab2 
transcription is directly regulated by Egr1 47. As measured with both microarrays and 
quantitative RT-PCR, Nab2 expression was up-regulated in cardiac hypertrophy and 
was further elevated in Nkx2-5+/-/CnA-Tg hearts (CnA-Ntg vs. CnA-Tg, P = 0.02; 
Nkx2-5 WT/CnA-Tg vs. Nkx2-5+/-/CnA-Tg, P = 0.03; Fig. 3.2c). Nab2 expression 
level, however, was not responsive to Nkx2-5 dosage under baseline conditions (P = 
0.86; Fig. 3.2c). Lastly, the Nkx2-5 level was halved, as expected, in Nkx2-5+/- hearts 
under both baseline and hypertrophic conditions (P = 0.02 and 0.05, respectively; Fig. 
3.2c). Nkx2-5 was not differentially regulated in response to calcineurin 
overexpression regardless of Nkx2-5 dosage. 
Nkx2-5 physically interacts with Egr1 and Nab1 
To establish the role for Nkx2-5 as a co-regulator of Egr1-dependent 
transcriptional activation, an in vitro binding assay was carried out to assess potential 
protein-protein interactions between Nkx2-5 and Egr1 (Fig. 3.3a). 35S-labeled Egr1 
and Egr1 suppressor Nab1 were both shown to bind to Nkx2-5 fused to maltose 
binding protein (MBP-Nkx2-5) immobilized on amylose beads. Known interactions 
between Nab1 and Egr1 94, and between Gata4 and Nkx2-5 95, were demonstrated as 
positive controls. 35S-labeled Gata-4 did not bind to MBP-Egr1, indicating that 
specificity was maintained in the assay. Additionally, the Nkx2-5 protein domain 
required for the physical interaction between Nkx2-5 and Egr1 was determined with 
an in vitro binding assay between MBP-Egr1 and 35S-labeled Nkx2-5 mutants with N- 
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and C-terminal truncations for known functional domains. As shown in Figure 3.3b, 
only those Nkx2-5 fragments containing the homeodomain were able to bind to 
MBP-Egr1 in vitro. The homeodomain had previously been shown to be necessary for 
the protein-protein interaction between Nkx2-5 and Gata-4 95, despite being primarily 
known for its DNA binding activity. As a control, the same set of 35S-labeled Nkx2-5 
deletion mutants was tested against MBP-Nkx2-5 to recapitulate results from previous 
reports that Nkx2-5 homodimerizes via an interaction between homeodomains 95,96. 
The NK2SD domain adjacent to the homeodomain in the C-terminal direction 
contributes to the Egr1-Nkx2-5 interaction and Nkx2-5 homodimerization. Nkx2-5 
fragment B, which retained the homeodomain but not the NK2SD domain, was able 
to bind to both MBP-Egr1 and MBP-Nkx2-5, albeit with reduced affinity. 
Nkx2-5, along with Nab1, modulate Egr1-dependent transcriptional activation 
Nab2 expression is regulated by Egr1 47 and is sensitive to Nkx2-5 dosage in 
the context of calcineurin overexpression-induced cardiac hypertrophy (Fig. 3.2c). To 
ascertain the function of Egr1-Nkx2-5 interaction, a transactivation assay was carried 
out in C2C12 myoblasts using a luciferase reporter construct driven by the murine 
Nab2 proximal promoter (Fig. 3.3c). The introduction of exogenous Egr1 alone 
activated the luciferase reporter as expected (P < 0.0001). The addition of Nkx2-5 or 
Nab1 had no effect on the baseline activity of the Nab2 promoter, but both were able 
to attenuate Egr1-activated reporter activity (P < 0.0001 for both). Egr1-dependent 
activation of the Nab2 promoter was maximally suppressed when Nkx2-5 and Nab1 
were added to the reaction in combination (P < 0.0001). 
Given that the paralogs Nab2 and Nab1 share structural and functional 
features and may be partially interchangeable, it is conceivable that Nab2 may itself 
exert some effect on Egr1-dependent transcriptional regulation. A follow-up 
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transactivation experiment showed that the addition of Nab2 diminished the collective 
repressive effect by Nkx2-5 and Nab1 on the Egr1-dependent activation of the Nab2 
promoter (Fig. 3.3d). This modulatory effect of Nab2 on Egr1-dependent 
transcriptional regulation was dependent on Nab2 concentration (R = 0.88; P = 
0.0002). In contrast, the addition of GFP in increasing concentrations had no effect on 
the Egr1-dependent activation of the Nab2 promoter (R = -0.22; P = 0.59). These 
findings suggest that the transcriptional activation of Nab2 may constitute a feed 
forward feature in Egr1-dependent transcriptional regulation in the pathogenesis of 
cardiac hypertrophy.  
Heterozygous deletion of Nab2 reduced the severity of cardiac hypertrophy in 
CnA-Tg mice 
The results from the in vitro transactivation experiments predicted that a 
decrease in Nab2 expression may impede Egr1-dependent activation of target gene 
expression and thus curtail the development of cardiac hypertrophy. We tested this 
hypothesis genetically by measuring the extent of cardiac hypertrophy in 35-day old 
wild-type, Nab1+/- and Nab2+/- mice overexpressing calcineurin. Under baseline 
conditions, the heart weight to body weight ratio in both Nab1+/- and Nab2+/- mice was 
not significantly different from with the ratio in their wild-type counterparts (4.8±0.1 
mg/g in wild-type vs. 4.7±0.1 mg/g in Nab1+/-; P = 0.72, and vs. 4.7±0.1 mg/g in 
Nab2+/-; P = 0.66; Fig. 3.4a). In calcineurin overexpression-induced cardiac 
hypertrophy, Nab2+/- mice had a 10.4±3% lower HW/BW ratio in comparison to their 
wild-type littermates (11.4±0.3 mg/g in Nab2-WT/CnA-Tg vs. 10.2±0.2 mg/g in 
Nab2+/-/CnA-Tg; P = 0.05; Fig. 3.4a). In contrast, the HW/BW ratio in Nab1+/- mice 
was not significantly different from that in the wild-type mice under hypertrophic 
conditions (11.4±0.3 mg/g in Nab1-WT/CnA-Tg vs. 11.2±0.3 mg/g in 
Nab1+/-/CnA-Tg; P = 0.62; Fig. 3.4a). In contrast to Nkx2-5, Nab1 and Nab2 
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haploinsufficiency did not lead to an increased lung weight to body weight ratio under 
hypertrophic conditions (Fig. 3.4a). Reduced Nab2 dosage also affected mean 
survival time in animals with cardiac hypertrophy. When subjected to calcineurin 
overexpression-induced hypertrophic stress, Nab2+/- mice demonstrated a prolonged 
lifespan relative to their wild-type and Nab1+/- littermates (149±17 days in 
Nab2+/-/CnA-Tg vs. 96±12 days in CnA-Tg; P = 0.02, and vs. 124±25 days in 
Nab1+/-/CnA-Tg; P = 0.03; Fig. 3.4b). 
The expression pattern of the cardiac hypertrophy marker genes ANF and 
Myh7, but not BNP, reflected the attenuated hypertrophic response to calcineurin 
overexpression in Nab2+/- mice. The up-regulation associated with pathological 
cardiac hypertrophy of ANF and Myh7 was blunted in Nab2+/- hearts in comparison to 
wild-type hearts in a quantitative RT-PCR analysis (P = 0.01 and 0.05; Fig. 3.4c). 
mRNA expression of transcriptional regulators was also differentially regulated to 
varying degrees in Nab animals. The elevated Egr1 mRNA level under hypertrophic 
conditions did not vary significantly among wild-type, Nab1+/-, and Nab2+/- hearts 
(Fig. 3.4d). Similarly, Nkx2-5 and Nab1 expression levels were not responsive to a 
reduced dosage of Nab2 or the hypertrophic status of the hearts (Fig. 3.4d). Nab2 
expression, however, was up-regulated in cardiac hypertrophy except in Nab2+/- hearts 
(CnA-Ntg vs. CnA-Tg, P = 0.02; Nab1+/- vs. Nab1+/-/CnA-Tg, P = 0.01; Nab2+/- vs. 
Nab2+/-/CnA-Tg, P = 0.32; Fig. 3.4d). Notably, Nab2 mRNA level was elevated in 
Nab1+/- hearts, irrespective of the hearts’ state of hypertrophy (Nab1 WT/CnA-Ntg vs. 
Nab1+/-/CnA-Ntg, P = 0.01; Nab1 WT/CnA-Tg vs. Nab1+/-/CnA-Tg, P = 0.05), 
suggesting that Nab1-dependent suppression of Nab2 expression is independent of 
cardiac hypertrophy. Together, these results point to a context-dependent network of 
regulation arising from an intricate interplay among Egr1, Nab1, Nab2, and Nkx2-5. 
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DISCUSSION 
Nkx2-5 has been extensively studied in fetal heart development but remains 
relatively unexplored in adults. In this study, we hypothesized that postnatal Nkx2-5 
expression may modulate the pathogenesis of adult heart disease, so we set out to 
characterize Nkx2-5+/- mice in the context of cardiac hypertrophy. Nkx2-5+/- mice 
express half the normal level of Nkx2-5 mRNA and protein, which presumably 
approximates naturally-occurring variations in the normal physiological range of 
Nkx2-5 levels more closely than either knockout or overexpression models 97. In the 
absence of hypertrophic stress, adult Nkx2-5+/- mice with no CHDs lack a readily 
detectable morphological or physiological phenotype. When challenged with 
pathologic surgical or genetic stimuli, however, Nkx2-5+/- mice exhibited markedly 
enhanced cardiac hypertrophy and poorer survival outcomes than their wild-types 
littermates. A set of unbiased computational screens was applied to identify the 
mechanisms underlying the Nkx2-5 dosage dependence of hypertrophic responses in 
the heart. These analyses combined orthogonal datasets of disparate experimental 
origins to generate a mechanistic hypothesis that Nkx2-5 influences the pathogenesis 
of cardiac hypertrophy in part by modulating the transcription program regulated by 
Egr1, a known mediator of cardiac hypertrophy. Experimental validations in this 
study subsequently confirmed that Nkx2-5 physically interacts with Egr1 and its 
specific repressor Nab1 to suppress Egr1-dependent transcriptional activation in 
cardiac hypertrophy. Whether Nkx2-5-dependent repression of Egr1-dependent 
transcription requires physical interaction between Nkx2-5 and DNA in the target 
promoter remains an open question. Computational dynamics modeling and further 
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experimental investigations are required to reveal the full mechanistic details of the 
Nkx2-5-Egr1-Nab1 interaction. 
Nab2, a Nab1 paralog, was identified in our screen as a prototypical Nkx2-5 
dosage-sensitive target gene under Egr1-dependent transcriptional regulation in the 
context of pathological cardiac hypertrophy. In our mouse models, the mRNA 
expression level of Nab2 corresponds to the severity of hypertrophic response. A 
causal relationship between elevated Nab2 expression and increased cardiac 
hypertrophy is supported by a transactivation experiment in which the addition of 
Nab2 negated the suppression of Egr1 activity by Nab1 and Nkx2-5 in a 
concentration-dependent manner. The effect of Nab2 on the pathogenesis of cardiac 
hypertrophy was confirmed genetically in the Nab2+/-/CnA-Tg mice, in which reduced 
Nab2 dosage attenuated the hypertrophic response to calcineurin overexpression and 
prolonged survival. Egr1-dependent expression of Nab2 may constitute a novel feed 
forward mechanism in the pathogenesis of cardiac hypertrophy. However, Nab2 has 
also previously been described as a suppressor of Egr1-dependent transcription 98. The 
role for Nab2 may therefore be context-dependent, and requires further 
characterization. The novel findings from this study are summarized in Figure 3.5. 
In the last two decades, over-expression and knockout models have been 
established as invaluable tools to study gene function. The expression levels of genes 
under study, from nearly zero in null models to up to several thousand times the 
wild-type level in overexpression models, departs drastically from what is 
physiologically plausible in complex biological processes with multiple layers of 
amplification and feedback regulation. The mechanistic insights derived from the 
dramatic phenotype in these studies are often qualitative in nature. For instance, 
previous studies of Nkx2-5 function in the postnatal heart have linked large deviations 
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from the physiological range of Nkx2-5 dosage to the development of cardiomyopathy 
34,79,82. The mechanisms associated with these dramatic phenotypes, however, may not 
be directly relevant in the understanding of similar pathologies in human patients. 
Modern genomic methods, with ever-greater capacities to generate larger and more 
accurate datasets, greatly enhance our ability to identify mechanisms underlying 
subtle and previously undetectable phenotypic observations. The modest scale of 
differential gene expression involved in governing such regulatory mechanisms belies 
their true biological significance. As an example, our study highlights the importance 
of precise gene dosage regulation in the upstream regulators Egr1 and Nkx2-5 in the 
context of a major disease process. In general, a haploinsufficient animal model that is 
indistinguishable from wild-type littermates under normal conditions but that 
responds differently under pathological conditions may provide a closer 
approximation of real world health and disease than either null models or 
overexpression models can deliver. 
Lastly, we demonstrated the utility of computational screens as a tool to rapidly 
generate testable hypotheses in the laboratory. In this study, computational analyses 
were carried out using data generated internally as well as data freely available from 
public depositories. The analyses were designed to target a specific class of 
hypothetical mechanisms underlying the phenotypic observations manifested in the 
Nkx2-5+/- mice. Validation experiments were then performed to inform the subsequent 
computational analyses. This iterative and hybrid approach for solving biological 
problems may substantially accelerate discoveries and reduce research costs; we were 
able to identify novel molecular interactions among transcriptional regulators Egr1, 
Nab1, and Nkx2-5, and a functionally relevant downstream target gene, Nab2, despite 
the limitations inherent in our computational screen, which was designed to reduce 
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the complexity of the analyses. These limitations include: focusing solely on 
transcriptionally regulated mechanisms, using stringent criteria to exclude additional 
candidate transcriptional regulators and target genes in the TFBS screen, and limiting 
the analyses to relatively small regions in the proximal promoters. Given the 
ever-increasing volume and quality of data deposited in the public domain, we expect 
computational screens to become a routine and ubiquitous part of biomedical research. 
Further developments of this computational method are necessary in order to expand 
its capabilities and enhance its usability to capitalize on the deluge of data from 
modern biomedical studies. 
 
METHODS 
Mouse husbandry and genotyping 
Nkx2-5 knockout mice were generated by targeted replacement of the entire 
coding region with β-galactosidase, as has been previously described 80. The Nkx2-5 
strain is maintained in a C57Bl/6 background after >6 backcrosses. Calcineurin 
transgenic mice were kindly provided by Dr. Jeff Molkentin, and were maintained by 
mating transgenic males to hybrid B6C3F1 females 21. B6C3F1 mice were purchased 
from Charles River Laboratories. Nab1 and Nab2 mice 99 were a generous gift from 
Dr. Jeff Milbrandt (Washington University School of Medicine, St. Louis, MO). All 
protocols conformed with the protocols of the Association for the Assessment and 
Accreditation of Laboratory Animal Care and are approved by the animal studies 
committee at Washington University School of Medicine. 
Transverse aortic constriction model of cardiac hypertrophy 
Male mice, aged 8-10 weeks and weighing 22-25 g, were subjected to 
transverse aortic banding to induce cardiac hypertrophy, or to a sham operation. 
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Pentobarbital (70 mg/kg intraperitoneal) was given for general anesthesia. Each 
mouse was positioned supine, and the trachea orally intubated for mechanical 
ventilation. After subcutaneous injection of 1% lidocaine (0.1 ml) for local anesthesia, 
an incision was made into the left second intercostal space. The aortic arch was 
mobilized. The right innominate, left carotid and left subclavian arteries clearly 
visualized. A 7-0 silk suture was passed around the transverse aorta between the 
innominate and left carotid arteries and tied against a 27-gauge needle to create a 
stenotic band. The needle was removed and the chest closed by suturing each layer of 
muscle and skin. The mouse remained intubated until resumption of spontaneous 
respiration. The animals were allowed to recover under warming lights or on warming 
pads until they were fully awake. Sham-operated mice underwent the entire 
procedure, including dissection of the aortic arch, but not banding. The duration of the 
operation was 20-25 minutes. 
Heart weight measurement 
Subjects were sacrificed between 35-39 days of age. Measurement of the body 
weight, heart weight, lung weight, and tibia length were taken immediately following 
dissection. 
Cell culture 
The C2C12 pre-myocyte cell line was purchased from the ATCC (Manassas, 
Virginia) and maintained according to protocol supplied by the vendor 
(http://www.atcc.org/). C2C12 cells were transfected using Lipofectamine 2000 
(Invitrogen) as per the manufacturer’s instructions. Transfected cells were maintained 
for an additional 36 hours following transient transfection before harvest. 
RNA extraction 
RNA was isolated from the ventricles using Trizol reagent (Invitrogen) 
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following the manufacturer’s protocol. Ventricular tissues stored in -80oC were 
homogenized in Trizol using the PowerGen 125 homogenizer (Fisher Scientific). The 
precipitated RNA was resuspended in 175 µL of RNA lysis buffer from the SV Total 
RNA Isolation Kit (Promega, Madison, WI) and purified according to the 
manufacturer’s protocol. cDNA was synthesized from 2.5 µg of total RNA using 
SuperScript VILO cDNA Synthesis Kit (Invitrogen) according to manufacturer’s 
protocol. 
Quantitative PCR 
Quantitative PCR of cDNA was performed in Mx3005P QPCR System 
(Stratagene, Santa Clara, CA) in a 40µL reaction containing iQ SYBR Green 
Supermix (Bio-Rad) and PCR primers at a final concentration of 200 nM. Primer 
sequences were designed with the PerlPrimer 75 or obtained from PrimerBank 76. 
Primers were purchased from Sigma Aldrich or Integrated DNA Technologies 
(Coralville, IA). The primer sequences are provided in the supplemental methods. 
Relative mRNA expression was determined using the ΔΔ-Ct method and normalized 
to Actb. 
Expression profiling  
Expression profiles of four calcineurin transgenic ventricles (CnA-Tg) and 
four non-transgenic ventricles (CnA-Ntg) from five-week-old males were generated 
using Affymetrix U74Av2 chips. Expression profiles were scaled with the MAS5.0 
software (Affymetrix) and normalized by mean. Expression profiles for FVB mice 
subjected to either TAC or sham operations were obtained from the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) 39 under series accession number 
GSC1621 87. Differential gene expression was detected using profile ANOVA in 
61 
 
Spotfire DecisionSite v9.1 (TIBCO, Palo Alto, CA). GO terms over-represented in 
differentially expressed genes were identified using Genemerge 74. 
Computational analysis 
An algorithm modified from Mootha et al. 100 was used to correlate the 
presences of mammalian TRANSFAC motifs 88 within the 2.5 kb of proximal 
promoters (-2000bps to +500bps relative to annotated transcriptional start sites) to 
differential gene expressions. Promoter sequences were extracted from mouse genome 
mm8 build based on Refgene annotations and assigned a significance rank derived 
from the p-values associated with differential expression in the genes they represent in 
a particular expression profile experiment. For each transcription factor binding site 
(TFBS) profile, the algorithm first identifies the best instance within each proximal 
promoter sequence as previously described 101-103 at every base position, both in the 
forward and reverse orientations. A dynamic score threshold is then used to make 
presence/absence calls for that TFBS profile within each promoter. The algorithm 
thus does not take into account multiple occurrences of weaker TFBSs in a given 
promoter. For each TFBS profile, the significance rank associated with presence and 
absence calls obtained at every step of bit-score thresholding is evaluated using 
ranksum statistics. P-values from the ranksum test were corrected for multiple 
hypotheses testing using false discovery rate calculations.  
In vitro binding assay 
MBP-fusion proteins were expressed in BL21 DE3 competent cells in rich 
media containing 0.3mM IPTG. Fusion proteins were released by sonication and 
bound to amylose resins. 35S-methionine-labeled Egr1, Nkx2-5, Nab1, and Gata-4 
were expressed using T7-coupled reticulocyte lysate system (Promega). Radiolabeled 
proteins were incubated in binding buffer with fusion protein bound amylose resins 
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for 4 hours in 4oC and electrophoresed by SDS-PAGE. Binding between radiolabeled 
proteins and MBP-fusion proteins were detected with autoradiography. 
Measurement of whole-cell membrane capacitance 
Myocytes were isolated using procedures previously described 104. Briefly, 
hearts were mounted on a Langendorf apparatus and perfused in a retrograde direction 
through the aorta with a buffer containing 0.8 mg/ml collagenase (type II, 
Worthington Biochemical Corp., Lakewood, NJ) 105. Following the perfusion, the LV 
apex was dissected, mechanically dispersed and plated on laminin-coated coverslips 
and maintained in 5% CO2. Whole-cell recordings were obtained from LV apex 
myocytes within 24 hours at room temperature. All voltage-clamp experiments were 
performed using an Axopatch 1B patch clamp amplifier (Molecular Devices, 
Sunnyvale, CA) and the pCLAMP9 software package (Molecular Devices). Data were 
filtered at 5 kHz before storage. Voltage-clamp data were compiled and analysed 
using Clampfit v.9.2 (Molecular Devices) and Microsoft Excel. Capacitative 
transients recorded in brief ±10 mV voltage steps from the holding potential (−70 
mV) were integrated to yield the whole-cell membrane capacitance (Cm). 
Measurement of Cardiomyocyte Cross-sectional Areas 
Mice were anesthetized with a terminal dose (120 mg/kg) of sodium 
pentobarbital via intraperitoneal injection. The sedated animals were perfused with 10 
mL of phosphate buffered saline containing 10 mg of heparin (Sigma), followed by 
100 mL of 4% paraformaldehyde (PFA) in 0.1 M sodium phosphate buffer (pH 7.2 at 
20 °C) in a 20 mL/minute drip using a peristaltic pump. The hearts were then excised 
and fixed in 4% PFA for an additional hour. After dehydration in 70% ethanol 
overnight, the fixed hearts were embedded, sectioned, and stained with Masson's 
trichrome. Microscopy images (20X objective lens) of the heart sections were 
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captured using Zeiss Axiovision software. For each heart, 60 cardiomyocytes oriented 
perpendicular to the section plane were highlighted using Adobe Photoshop. The 
cross-sectional area of each highlighted cells were then determined using NIH 
ImageJ. 
Cloning and Plasmids 
Dr. Jeff Milbrandt (Washington University School of Medicine, St. Louis, 
MO) generously provided the following clones: pCB6 HA-Egr1, pCITE Egr1, FCIV 
HA-Nab1, CMVneo His-Nab1, and pcDNA3 Nab2. Murine Nkx2-5 in pcDNA3.1 and 
pMAL vectors were a gift from Dr. Seigo Izumo. SV40-renilla luciferase in pGL4 
was obtained through Promega. Egr1, Nkx2-5 and Nkx2-5 fragments were cloned 
from the expression vectors into pMALc2 vector (NEB) for in vitro expression of 
maltose binding protein (MBP) fusion proteins. Primers used for cloning Nkx2-5 
fragments are listed in Supplementary Table S3.3. Nab2 promoter from -2000 bps to 
+500 bps was cloned from genomic DNA of a C57Bl/6 donor by PCR using primers 
listed in Supplementary Table S3.3. PCR product was cloned into pCRII cloning 
vector using the PCRII TOPO TA Cloning Kit (Invitrogen). The Nab2 promoter was 
subsequently sub-cloned into a pGL3 luciferase vector (Promega) at the unique XhoI 
and HindIII site. Clones in ‘plus’ orientation were screened by restriction digestions 
and sequence verified. 
Transactivation Assay 
C2C12 pre-myocytes cultured in 24 well plates were transfected with 0.4mg of 
Nab2 luciferase reporter construct and 0.01mg of SV40 renilla luciferase construct, 
with or without activators Egr1, Nkx2-5, and Nab1. The transactivation assay was 
carried out immediately following cell harvest using the Dual-Luciferase Reporter 
Assay System (Promega) following the manufacturer’s instructions. Nab2 luciferase 
64 
 
activity was measured in 10 seconds intervals in a Leader 50i luminometer 
(Gen-Probe, San Diego, CA) serially. Nab2 luciferase activity measurements were 
normalized to SV40-driven renilla luciferase readings measured in the same reaction. 
Statistics 
Two-tailed student’s t-tests were used to access the significance level in all 
pair-wise comparisons. The significance levels of Venn logic were calculated using 
cumulative probability assuming hypergeometric distribution. All errors were 
reported as ± s.e.m. 
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FIGURES 
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Figure 3.1: Nkx2-5 haploinsufficiency led to the exacerbated cardiac hypertrophy and 
poor prognosis in response to pathological hypertrophic stimuli. (a) Cardiac 
hypertrophy developed following transverse aortic constriction was enhanced In 
Nkx2-5 haploinsufficient (Nkx2-5+/-) mice in comparison to wild-type (WT) 
littermates (p=0.011). Nkx2-5 haploinsufficiency has no appreciable phenotype in 
sham-operated mice. (b) The extent of cardiac hypertrophy developed following the 
overexpression of calcineurin transgene was roughly doubled in Nkx2-5+/-/CnA-Tg 
hearts in comparison to CnA-Tg hearts (p<0.001). Nkx2-5 WT and Nkx2-5+/- hearts 
showed no difference in terms of cardiac mass under baseline conditions. n = 6-18 per 
genotype group. (c) Nkx2-5+/-/CnA-Tg hearts showed dramatic hypertrophy in 
comparison to wild-type hearts as a result of calcineurin overexpression at 35 days of 
age (bottom row). Nkx2-5 WT and Nkx2-5+/- hearts were indistinguishable 
morphologically under baseline conditions (top row). The white scale bar indicates 
10mm. (d) Cross-sectional area of ventricular cardiomyocytes was greater in the 
Nkx2-5+/-/CnA-Tg hearts in comparison to CnA-Tg hearts. Nkx2-5 dosage had no 
effect on the cross-sectional areas in non-transgenic (CnA-Ntg) cardiomyocytes. n = 
60 per group. (e) Whole cell membrane capacitance was increased by 39% and 60%, 
respectively, in the CnA-Tg and Nkx2-5+/-/CnA-Tg hearts in comparison to their 
non-transgenic counterparts (p=0.038). Nkx2-5 dosage had no effect on the whole cell 
membrane capacitance values in non-transgenic (CnA-Ntg) cardiomyocytes. n = 60 
per group. (f) CnA-Tg mice die prematurely due to heart failure (median = 196 days, 
solid tracing). The median survival time for Nkx2-5+/-/CnA-Tg mice was reduced to 72 
days for the male (n = 4, dark dashed tracing, p=0.005). (g) Quantitative RT-PCR 
result showing mRNA expression level for selected cardiac hypertrophy markers 
differentially regulated in calcineurin overexpression induced cardiac hypertrophy 
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and Nkx2-5 haploinsufficiency (n = 4). For all panels, error bars indicate s.e.m. (*, P < 
0.05). 
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Nkx2-5 WT Nkx2-5+/- 
  CnA-Ntg CnA-Tg CnA-Ntg CnA-Tg 
HW/BW 4.27±0.08 8.95±0.22† 4.28±0.06 13.27±0.47*‡ 
LW/BW 6.15±0.06 5.95±0.14 6.26±0.11 6.88±0.06*‡ 
EDD 3.16±0.15 4.15±0.17† 3.12±0.10 4.21±0.14* 
ESD 1.41±0.19 2.72±0.27† 1.67±0.15 2.71±0.21* 
LVPW 0.65±0.03 0.82±0.02† 0.67±0.03 0.94±0.03*‡ 
FS 55.83±4.08 35.17±4.41† 46.89±3.45 36.17±3.39 
HR 527.50±25.88 445.17±36.11 485.67±32.67 439.17±53.94 
n 6 6 7 6 
 
Table 3.1: Physiologic parameters in wild-type (WT) and Nkx2-5+/- mice under 
baseline (CnA-Ntg) or hypertrophic (CnA-Tg) conditions. HW/BW: heart weight to 
body weight ratio (mg/g); LW/BW: heart weight to body weight ratio (mg/g); EDD: 
end-diastolic diameter (mm); ESD: end-systolic diameter (mm); LVPW: left 
ventricular posterior wall thickness (mm); FS: fractional shortening (%); HR: heart 
rate (min-1). †: P < 0.05 in the Nkx2-5 WT/CnA-Ntg vs. Nkx2-5 WT/CnA-Tg 
comparisons; ‡: < 0.05 in the Nkx2-5 WT/CnA-Tg vs. Nkx2-5+/-/CnA-Tg comparisons; 
*: < 0.05 in the Nkx2-5+/-/CnA-Ntg vs. Nkx2-5+/-/CnA-Tg comparisons.  
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Figure 3.2: Egr1 was identified in a computational screen as an Nkx2-5 
dosage-sensitive transcriptional regulator in the pathogenesis of cardiac hypertrophy. 
(a) A schematic of our computational strategy and results. Left: the numbers of probe 
sets up- and down-regulated in each of the comparisons are given next to the Venn 
diagrams adjacent to the model names. Center: the proximal promoter sequences for 
every gene represented on the microarray were curated and ordered based on the 
significance level of their differential regulation in each comparison. A ranksum test 
was then used to determine the correlation between the presence of a particular 
transcription factor binding site (TFBS) in the proximal promoters and differential 
gene expression. Right: The numbers of TFBS whose presence in the proximal 
promoters was associated with differential gene regulation at a false discovery rate of 
5% are given for each comparison in the Venn diagram. Egr1 was found in the 
intersection of all three TFBS lists. (b) The presence of Egr1 TFBS in the proximal 
promoters was associated with differential gene expression in all three comparisons 
(see Fig. 3.2a). The ranks of each gene, or probe set, ordered by the significance level 
of its differential expression in a given comparison, are represented on the horizontal 
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axis, with the most significant towards the left of the graph. The red tracings reflect 
the negative log of each gene’s ANOVA p-value in a given comparison. Each black 
hatch represents five successive Egr1 TFBS positive proximal promoters and is 
positioned at the centroid of the five promoters on x-axis. The p-values of the 
correlations are 0.001 (ranked 11th), 0.0001 (ranked 1st), and 0.002, (ranked 16th) in 
TAC, CnA-Tg, and Nkx2-5+/-/CnA-Tg models, respectively. (c) Quantitative RT-PCR 
results showing ventricular mRNA expression patterns of Egr1, Nab1, Nab2, and 
Nkx2-5 in calcineurin overexpression-induced cardiac hypertrophy and Nkx2-5 
haploinsufficiency. Error bars indicate s.e.m. (*, P < 0.05, n = 4). 
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Baseline vs. TAC and CnA-Tg 
 
GO Accession 
Population 
fraction 
Study 
fraction Description P-value 
0006817 53/7013 10/100 phosphate transport 1.6E-07 
0007155 266/7013 17/100 cell adhesion 4.9E-06 
0014037 3/7013 2/100 Schwann cell differentiation 1.2E-02 
0030162 4/7013 2/100 regulation of proteolysis 1.8E-02 
0001558 45/7013 4/100 regulation of cell growth 4.4E-02 
Nkx2-5 WT vs. Nkx2-5+/- 
   
GO Accession 
Population 
fraction 
Study 
fraction Description P-value 
0008152 254/7013 17/122 metabolism 9.0E-05 
0006099 20/7013 5/122 tricarboxylic acid cycle 5.3E-04 
0006631 44/7013 5/122 fatty acid metabolism 8.8E-03 
0006633 24/7013 4/122 fatty acid biosynthesis 1.0E-02 
0019439 3/7013 2/122 aromatic compound catabolism 1.0E-02 
0007031 10/7013 3/122 
peroxisome organization and 
biogenesis 1.1E-02 
0001662 4/7013 2/122 behavioral fear response 1.4E-02 
0008542 5/7013 2/122 visual learning 2.1E-02 
0001676 6/7013 2/122 long-chain fatty acid metabolism 2.7E-02 
0006725 7/7013 2/122 aromatic compound metabolism 3.1E-02 
0009083 7/7013 2/122 
branched chain family amino acid 
catabolism 3.4E-02 
0009636 9/7013 2/122 response to toxin 3.8E-02 
0042593 9/7013 2/122 glucose homeostasis 4.1E-02 
0006629 103/7013 6/122 lipid metabolism 4.2E-02 
0006637 9/7013 2/122 acyl-CoA metabolism 4.4E-02 
0006749 10/7013 2/122 glutathione metabolism 4.4E-02 
  
Table 3.2: Gene Ontology (GO) terms associated with differential gene expression in 
cardiac hypertrophy and Nkx2-5 haploinsufficiency.   
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Figure 3.3: Nkx2-5 interacts with Egr1 and Nab1 to modulate Egr1-dependent 
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transcriptional activation in the proximal promoter of candidate target gene Nab2. (a) 
In vitro binding assay showing 35S-labeled Egr1 physically interacting with 
immobilized full length Nkx2-5 (lane 1) and a C-terminal fragment of Nkx2-5 
(fragment F, aa137-318, lane 3) but not a N-terminal fragment (fragment A, aa1-136). 
35S-labeled Nab1 also physically interacted with MBP-Nkx2-5 (lane 6). Previously 
described Egr1- Nab1 (lane 5) and Nkx2-5-Gata-4 (lane 9) interactions were included 
as controls. (b) 35S-labeled truncation fragments of Nkx2-5 were tested for interaction 
with MBP-Egr1 or MBP-Nkx2-5 to determine the Nkx2-5 protein domain involved in 
these protein-protein interactions. The fragments are shown as grey arrows below a 
schematic drawing of Nkx2-5 structure. The darker shade indicates Nkx2-5 fragments 
in which MBP-Egr1 binding activity is preserved. The 35S signals retained from 
positive interactions to MBP-Egr1 and MBP-Nkx2-5 were normalized to the input 
signals and shown on the right. (c) A transactivation assay demonstrating the effect of 
Nab1 and Nkx2-5 on Egr1-dependent activation of the Nab2 proximal promoter 
(-2000-+500 relative to annotated transcriptional start site). The addition of Egr1 
alone activated the Nab2 promoter. Nkx2-5 and Nab1 both had a suppressive effect on 
Egr1-dependent transcriptional activation of the Nab2 promoter. (d) A transactivation 
assay demonstrating the effect of Nab2 on the Nab1/Nkx2-5-dependent suppression of 
Egr1-dependent activation of the Nab2 promoter. The addition of an increasing 
concentration of Nab2 reduced the suppressive effect of Nab1 and Nkx2-5 on 
Egr1-dependent activation of the Nab2 promoter, but the addition of an increasing 
concentration of GFP did not. For all panels, error bars indicate s.e.m. (*, P < 0.05 
compared with luciferase activity when only Egr1 was present, unless otherwise 
indicated, n = 4). 
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Figure 3.4: Reduced Nab2 gene dosage modifies the phenotype in the CnA-Tg model 
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of cardiac hypertrophy. (a) Calcineurin overexpression-induced cardiac hypertrophy 
was attenuated in Nab2+/- mice. (P = 0.05, n = 6-11). Nab1 or Nab2 
haploinsufficiency did not affect the cardiac mass under baseline conditions. Lung 
weight was unaffected by changes in Nab1 or Nab2 level under baseline or 
hypertrophic conditions. (b) A Kaplan-Meier plot showing improved survival in 
Nab2+/- animals compared with wild-type (WT) and Nab1+/- littermates under 
hypertrophic conditions (P = 0.02 and 0.03, respectively, n = 6-11). (c) Quantitative 
RT-PCR results showing the ventricular mRNA expression patterns of cardiac 
hypertrophy markers ANF, BNP, Myh6, and Myh7 under baseline or hypertrophic 
conditions in WT, Nab1+/-, and Nab2+/- animals. Error bars indicate s.e.m. (*, P < 0.05, 
n = 4). (d) Quantitative RT-PCR results showing the ventricular mRNA expression 
patterns of transcriptional regulators Egr1, Nab1, Nab2, and Nkx2-5 under baseline or 
hypertrophic conditions in WT, Nab1+/-, and Nab2+/- animals. Error bars indicate 
s.e.m. (*, P < 0.05; ns, not significant; n = 4). 
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Figure 3.5: A model outlining the proposed mechanism underlying the phenotype of 
Nkx2-5+/- and Nab2+/- animals in pathological cardiac hypertrophy. 
 
Supplementary Table S3.1: (Attached) Differential gene expression in mouse 
models of cardiac hypertrophy and Nkx2-5 haploinsufficiency. Separate tables 
corresponding to the Venn diagrams shown in Figure 3.2a (left) are provided. 
Supplementary Table S3.2: (Attached) Results from the TFBS screens. Separate 
tables corresponding to the Venn diagrams shown in Figure 3.2a (right) are provided. 
The ‘TF_ACCESSION’, ‘TF_ID’, and ‘TF_NAME’ fields contain the official 
accession numbers, IDs, and names for each TFBS in the TRANSFAC dataset. 
‘Maximum Score’ field contains the best possible scores for each TFBS under the 
scoring model used. The ‘Best Z Score’, ‘PV’, and ‘Rank’ fields contain the ranksum 
z-scores, the corresponding p-values, and the ranks (lower is more significant) for 
each TFBS within the models compared, using the optimal scoring threshold recorded 
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in the ‘Scoring Threshold’ field to determine the presence of the particular TFBS in 
the proximal promoters. Repeated TFBS entries with higher ranks were removed to 
render the TFBS records unique. 
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qRT-PCR:  
Probes Forward/Reverse 
Nkx2-5 AGTGCTCTCCTGCTTTCC/CTTTGTCCAGCTCCACTG 
Actb GCGTGACATCAAAGAGAAGC/AGGATTCCATACCCAAGAAGG 
Nppa GCAGAGACAGCAAACATCAG/TCTAGCAGGTTCTTGAAATCCA 
Nppb CAGAGACAGCTCTTGAAGGA/AACAACTTCAGTGCGTTACAG 
Egr1 TCGGCTCCTTTCCTCACTCA/CTCATAGGGTTGTTCGCTCGG 
Nab1 CTGATGGACAAGGAGAAAGAC/TTTAGAATCCCAAGGCTCTC 
Myh6 GCCCAGTACCTCCGAAAGTC/GCCTTAACATACTCCTCCTTGTC 
Myh7 ACTGTCAACACTAAGAGGGTCA/TTGGATGATTTGATCTTCCAGGG 
Nab2 TGGCAGAGGGGATAACACAC/CGTTGCAGGACCCGATACAG 
  
Genotyping:  
Nab1 Genotype WT For GGTCCATGTATTTTGCATATTTCTTATTT 
Nab1 Genotype KO For GCATCACAAATTTCACAAATAAAGCATTTT 
Nab1 Genotype Com Rev CACAGACTTGATGTGATTTCAGTCATTCTT 
Nab2 Genotype 9598 CTTCTCGAGCACTGCCCGCCTTTTCTC 
Nab2 Genotype 9599 GGAATTCGCCATGGCACTGCCTC 
Nab2 Genotype 9600 ACGGGCGTCCGCGTCGTTGTTTG 
Nab2 Genotype 9601 CTTCGCCCAATAGCAGCCAGTCC 
Nkx2-5 PB Forward? GACAAAGCCGAGACGGATGG 
Nkx2-5 PB Reverse? CTGTCGCTTGCACTTGTAGC 
CnA genotyping forward  
CnA genotyping reverse  
  
Nab2 Cloning:  
Nab2 Genomic PCR -2097 AGCCCCGCGCTAACAGGTTTAC 
Nab2 Genomic PCR +515 TCTTCTCCCCCTGCTCCAACATC 
Nab2 Promoter Cloning For AAAACTCGAGTTCTAACATTCAAACTAACGGCTCGGCGCGG 
Nab2 Promoter Cloning Rev AAAAAAGCTTGAGTGGCGACAACTTCTCTCCAAGTTCGAGG 
  
Nkx2-5 Fragments  
Csx pcDNA Cloning 1F AAA-GAATTC-GACACC-ATG-ttccccagccctgcgctcacacccac 
Csx pcDNA Cloning 137F AAA-GAATTC-GACACC-ATG-cgacggaagccacgcgtgctcttctcgcagg 
Csx pcDNA Cloning 208F AAA-GAATTC-GACACC-ATG-caggaccagactctggagcttctggggccg 
Csx pcDNA Cloning 251F AAA-GAATTC-GACACC-ATG-taccccagctacggcggcgcggcctgcag 
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Csx pcDNA Cloning 136R AAATCTAGACTACCGCCGTGCGCGTGGTCTCTCGG 
Csx pcDNA Cloning 207R AAATCTAGACTACGGCGGCCCCAGAAGCTCCAGAGTC 
Csx pcDNA Cloning 255R AAATCTAGACTAGGGGTAGGCGTTGTAGCCATAGGCA 
Csx pcDNA Cloning 313R AAATCTAGACTAGTGCAGCGTGGAGACGCCCGAATTG 
Csx pcDNA Cloning 318R AAATCTAGACTACCAGGCTCGGATGCCGTGCAGCGTG 
 
 
Supplementary Table S3.3: A list of primers used in the genotyping, cloning, and 
quantitative RT-PCR experiments described in the present study.  
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Chapter 4. Summary and Conclusion 
 
Transcription is a fundamental mechanism underlying the causality of an 
organism’s inherent genotype and its observed phenotype. Thus, study of 
transcriptional regulation forms the basis of modern molecular genetics. In 
development, tissue destined to make up each organ must express an appropriate set 
of genes which ultimately actualizes its form and function. This process is highly 
regulated through an intricate interplay between transcription factors and their target 
sequences in the genomic DNA. Transcriptional regulation is dynamic. Network of 
signaling proteins forms pathways directing the transcription factors to differentially 
regulate their target genes in response to normal or pathologic extrinsic stimuli. 
Understanding transcriptional regulation of a biological process is a critical step to 
gain the ability to modify the process and influence the outcome. As such, biomedical 
research efforts of the past few decades placed a major emphasis on prediction and 
linkage of novel transcriptional regulatory pathways to phenotype changes in 
development and disease. The advancement of high-throughput experimental 
methodology and computational biology offers unprecedented speed and ease to 
capture undiscovered regulatory pathways for detailed study in the context of specific 
biological processes. The work presented in this dissertation provides a computational 
framework to analyze datasets generated by high-throughput experimental methods. 
 
The analytical framework described here consists of two complementary 
approaches based on rank-sum statistics to identify such pathways. The first approach 
enables meta-analysis of large microarray datasets encompassing thousands of 
samples to predict tissue-specific gene expression patterns. Each gene’s expression 
pattern is summarized as a series of expression ranks in various tissues, thus making 
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tests of correlation to a phenotype of interest possible. This part of the analytical 
framework was applied to study various aspects of adipose tissue biology and obesity. 
The second approach correlates transcription factors to a transition in phenotype by 
detecting improbable relative abundance of specific transcription factor binding sites 
in the proximal promoters of genes differentially regulated in response to such 
transition. I applied this approach to study the modification of cardiac hypertrophy 
phenotype in mouse models by cardiac-specific transcription factor Nkx2-5. The 
computational methods set forth herein establish a flexible and unbiased mean of 
orthogonal data integration and rapid hypothesis generation.  
 
In addition to the development of computational methods, I have identified and 
characterized novel transcriptional regulators each of which represents a potential 
point of therapeutic intervention in major human diseases. In the preliminary study 
leading to the part of my thesis research pertaining to the induction of brown fat 
phenotype in WAT, my analytical framework furnished a focused and testable 
hypothesis that nuclear receptor Esrrg and a host of putative Esrrg targets share 
similar tissue-specific expression pattern as BAT master regulator Prdm16. This was 
achieved using only open-access public data at nearly no cost to our laboratory. In the 
validation experiments, I showed that Esrrg indeed functions to up-regulate BAT 
markers such as Ucp1 in adipocyte cell culture system. Specific inhibition of Esrrg 
with 4-OHT, an activated tamoxifen derivative, prevented the up-regulation of Ucp1 
in the WAT of mice subjected to long-term cold temperature exposure. I further 
identified Srebp1c as a co-regulator of Esrrg. Transfection of Srebp1c in Esrrg-rich 
myoblast cell line C2C12 results in strong up-regulation of BAT marker Ucp1. The 
addition of 4-OHT or co-transfection with vectors expressing Esrrg-targeting shRNA 
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in the same cell culture model attenuated Srebp1c-dependent Ucp1 up-regulation. 
Targeted delivery of Esrrg agonist may represent an attractive therapeutic strategy 
given the high interest in novel pharmaceutical treatments of obesity. 
 
My thesis research also made progress towards a more complete understanding 
of the pathogenic process in cardiac hypertrophy. By combining orthogonal datasets 
including expression profiles from multiple mouse models of cardiac hypertrophy, 
genomic sequences, and experimentally determined transcription factor profiles, my 
computational method predicted that the Egr1 pathway may be sensitive to Nkx2-5 
dosage which would account for the exacerbated cardiac hypertrophic response to 
detrimental stimuli observed in the Nkx2-5 haploinsufficient mice. This hypothesis 
was validated in vitro where a novel protein-protein interaction between Nkx2-5 and 
Egr1 was demonstrated. The functional consequence of this interaction appears to be 
the suppression of Egr1-dependent transcriptional activation. A target of this 
regulation is Nab2. Nab2 is a paralog of Egr1-specific repressor Nab1. Egr1-driven 
expression of Nab2 can interfere with Nab1-dependent suppression of Egr1, thus 
forming a feed forward loop. Indeed, male mice haploinsufficient for Nab2 have 
smaller hearts and improved survival in a yearlong validation study in vivo. While in 
no way challenging the value and validity of traditional gain- and loss-of function 
animal studies, my results suggest that small deviations in gene dosage can in fact 
lead to dramatic phenotypic differences even in complex multigenic diseases. Another 
unexpected, yet intriguing, discovery was the sexually dimorphic response to Nab 
gene dosage in the context of cardiac hypertrophy. While the male Nab mice behaved 
consistently with the predictions in silico and the results in vitro, the females did not. 
My results suggest that Nab2 is expressed at a higher level in the males at baseline 
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and contributes more towards the development of cardiac hypertrophy in the males 
compared to females. This may represent a first instance of sexually dimorphic 
mechanism at the level of transcriptional regulation in cardiac hypertrophy that does 
not involve sex hormones. 
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Chapter 5. Future Directions 
 
Several studies making novel use of tissue-specific gene lists are ongoing to 
accelerate discoveries and are generating a significant interest in this resource. In 
obesity, the white adipose tissue up-regulates specific adipokines, cytokines, and 
chemokines 12. Using ob mice as a model of obesity 106, I was able to correlate the 
differential regulation of chemokines in the obese WAT to specific immune cell 
targets by including the chemokine-receptor pairing information in the analysis. The 
results from this study may enhance our understanding of the cell-cell communication 
important in the pathogenesis of obesity. The interception of such communication 
may lead to a novel strategy to curtail the development of obesity. 
 
Another on-going project is the linkage analysis of atrial septal defect (ASD) in 
Nkx2-5+/- mice. Using microsatellite markers in a GWAS study, Julia Honold et al. 
were able to identify an allele that co-segregates with the development of ASD in 
Nkx2-5+/- neonates. 31 A typical allele resolved by microsatellite markers contains 
hundreds of known genes. Fine mapping, which is both cost and labor intensive, is 
therefore necessary to narrow down the causal gene within the genomic region. In a 
novel approach to this problem, we used the cardiac-specific gene list to prioritize 
candidate genes assuming that genes with highly restricted expression would likely be 
functionally important in the tissues they express in. We are currently focusing on 
sarcospan as a candidate modifier gene of Nkx2-5 in the context of ASD development. 
Sarcospan expression is highly specific in the heart, and plays a role in the 
development of muscular dystrophy 107,108. The preliminary results are near significant 
and encouraging. If successful, this approach can be adopted in any GWAS study 
where hypothesis can be reasonably made on the tissue-specificity of the causal gene. 
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Tissue specific gene lists can be useful in a scenario where one tissue takes on 
the function of another in a well-defined manner as exemplified in WAT to BAT 
transdifferentiation. Bielinska et al. have described development of adrenal tumors 
that produce sex hormones in gonadectomized mice 109. Transcription factor Gata4 is 
involved in the tumor development but the precise mechanism of tumorigenesis is not 
known. RNA-seq experiment to survey gene expression in the adrenal tumors is 
planned to gain further understanding of the tumorigenic process. The gonad-specific 
gene list can be applied here to facilitate the interpretation of the differential gene 
regulation associated with tumor transformation and sex hormone production. 
 
At the conclusion of the study described in Chapter 2, several topics were left 
unexplored and warrant further investigation. Our understanding of how promoter 
sequences encode instruction for tissue-specific expression is incomplete. At one 
point in my thesis research, I had attempted to correlate global tissue-specific gene 
expression to combinations of TFBSs found over-represented in the promoters of a 
training set of known tissue-specific genes. This approach had a limited yield since 
the TFBS input was not reliable. Revisiting this problem using data from the latest 
methods such as ChIP-seq may boost probability of success. A few issues also remain 
unresolved regarding the validation experiments. The study did not make clear 
whether the forced expression of BAT markers had any functional consequence in 
vitro and in vivo. Further metabolic and gene expression studies could help 
determining what the white adipose tissue expressing BAT markers actually represent 
functionally. Additionally, how the Esrrg pathway relates to the Prdm16 pathway is 
not known. Prdm16 expression was marginally up-regulated in the WAT following 
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exposure to cold and was not diminished in response to addition of 4-OHT. Prdm16 
may be necessary but insufficient in cold-induced BAT gene activation in WAT. 
Direct testing of Prdm16 in this context is needed to better define its functional 
relation to Esrrg. 
 
My work on Nkx2-5 haploinsufficiency described in Chapter 3 similarly opens 
opportunities for further study. While my results point to a model where Nkx2-5 
haploinsufficiency modifies target gene expressions through changes in the dynamics 
of physical interaction between Nkx2-5 and transcriptional co-regulators, they do not 
rule out a mechanism where Nkx2-5-DNA interactions are altered directly to cause 
differential gene regulation. To this end, I had unsuccessfully analyzed the proximal 
promoter sequences in differentially regulated genes in the Nkx2-5+/- hearts compared 
to wild-type hearts under non-hypertrophic conditions. Nkx2-5 ChIP data and more 
accurate and comprehensive surveying of global mRNA expression have since 
become available which may facilitate the discovery of promoter/enhancer sequence 
elements that specify Nkx2-5 dosage sensitivity. 
 
The conclusions from the series of animal studies carried out for this work may 
be bolstered by additional experiments. Due to the availability of mice and time and 
space constraints I was not able to directly characterize mice with reduced Egr1 
expression levels in the context of calcineurin overexpression induced cardiac 
hypertrophy. Similarly, how the Nab haploinsufficiency interacts with Nkx2-5 
haploinsufficiency in the context of cardiac hypertrophy has not been investigated in 
full. I hypothesize that, at least in the males, Nab2 haploinsufficiency may attenuate 
the enhanced hypertrophic response in the Nkx2-5+/-/CnA-Tg mice. Mice needed to 
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test this hypothesis currently are being bred in the Jay lab. In addition, the Nab 
haploinsufficient mice may be further characterized in a different model of cardiac 
hypertrophy such as the TAC model. Additional phenotyping experiments such as 
echocardiography and electrophysiology studies may be useful in establishing the 
functional consequences of Nab haploinsufficiency in the context of cardiac 
hypertrophy. 
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